ArgoRAD

UK Therapeutics
Triage Terminal

Shown

109

Avg quality score

51.0

Total raised

£4057M

VC/PE-backed

100%

Clinical-stage

Unique investors

433

▸ Pipeline analytics

Triage pipeline — click a stage to filter, click again to clear

→

Investor

Classification

Therapeutic dev.

Review

Excl. tools/dx

Excl. consumer/CDMO

Out of scope

Stage tier

Clinical

Near-clinical

Early / discovery

Not staged / excluded

Backing

Quick filter

Source

SV Deal Flow status

Modality

Min quality score

Company	Class.	Stage	Backing	Last Round	Investors	Raised £M	Staff	Growth	Quality▼
▸	CHARM Therapeutics London · f. 2021 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2025-09-02	Axial (San Francisco), Braavos Investment Advisers +14 more 16 investors	150.0	53	+39%	94
▸	Maxion Therapeutics Cambridge · f. 2020 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-02-15	BGF (Financial Services), British Business Bank +6 more 8 investors	105.1	50	—	90
▸	bit.bio Cambridge · f. 2016 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2026-01-09	ARCH Venture Partners, BlueYard Capital +32 more 34 investors	234.2	164	+8%	89
▸	Laverock Therapeutics London · f. 2021 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator 2025-09-01	Agronomics, Calculus Capital +11 more 13 investors	27.5	29	-7%	84
▸	NeoPhore Altrincham · f. 2017 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-01-05	3B Future Health Fund, 4basebio +19 more 21 investors	69.2	20	+19%	84
▸	NRG Therapeutics Stevenage · f. 2018 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-09-08	Arthur Roach, Brandon Biocatalyst +15 more 17 investors	95.0	7	+3%	83
▸	Orbit Discovery Oxford · f. — · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC	Borealis Ventures, Future Planet Capital +8 more 10 investors	16.5	31	—	83
▸	Curve Therapeutics Southampton · f. 2019 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-02-27	Advent Life Sciences, British Business Bank +4 more 6 investors	57.4	39	-16%	82
▸	AstronauTx London · f. 2019 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2023-10-02	Brandon Capital, Bristol-Myers Squibb +7 more 9 investors	68.8	10	0%	82
▸	Ogibiotec Edinburgh · f. 2019 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-06-13	Andrew Coleman, Apollo Informal Investment +11 more 13 investors	4.8	15	+45%	79
▸	Enara Bio Oxford · f. 2016 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-10-03	Blackwells Capital, M Ventures +5 more 7 investors	82.6	63	+42%	79
▸	Axol Bioscience Roslin · f. 2013 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2026-01-13	Amadeus Capital Partners, BroadOak Capital Partners +11 more 13 investors	19.9	46	+346%	79
▸	Mosaic Therapeutics London · f. 2020 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-10-20	Accelerate@Babraham, Cambridge Innovation Capital +4 more 6 investors	39.1	26	0%	74
▸	Locate Bio Nottingham · f. 2001 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-05-01	BGF (Financial Services), Heraeus Holding +5 more 7 investors	37.2	26	+50%	73
▸	Adendra London · f. 2021 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2023-12-12	Apple Tree Partners (ATP), Cancer Research Horizons +1 more 3 investors	53.5	3	0%	70
▸	Jellagen Cardiff · f. 2013 · Pharmaceuticals	Review	Near-clinical	Venture Capital-Backed	Later Stage VC	Angels Invest Wales, Cardiff Capital Region +9 more 11 investors	24.3	13	0%	70
▸	Amphista Therapeutics Cambridge · f. 2017 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-10-24	Advent Life Sciences, Eli Lilly and Company Foundation +7 more 9 investors	78.5	65	+66%	70
▸	Endlyz Therapeutics London · f. 2021 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Seed Round 2026-04-28	AbbVie Ventures, BioIndustry Association +5 more 7 investors	23.4	7	0%	70
▸	Sortera Bio Cambridge · f. 2023 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2025-05-29	AstraZeneca, BioNTech +1 more 3 investors	20.2	20	0%	68
▸	Carbometrics Bristol · f. 2018 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator 2025-01-01	Ada Ventures, Change Makers +8 more 10 investors	13.8	18	+4%	68
▸	CardiaTec Cambridge · f. 2021 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2026-01-01	APEX Ventures, Ascension (Private Equity) +16 more 18 investors	8.5	17	+125%	68
▸	Clock.bio Cambridge · f. 2020 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator	BlueYard Capital, Firstminute Capital +5 more 7 investors	10.0	10	—	67
▸	Kuano Cambridge · f. 2020 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator 2024-12-01	ACF Investors, AI Seed +16 more 18 investors	3.9	12	+5%	67
▸	SiSaf Guildford · f. 2006 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2023-04-04	Clarendon Fund Managers, Croda International +9 more 11 investors	43.3	18	—	67
▸	Vivan Therapeutics London · f. 2018 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Accelerator/Incubator	Arben Ventures, BioIndustry Association +15 more 17 investors	6.0	23	—	66
▸	Wobble Genomics Midlothian · f. 2020 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2024-03-07	BGF (Financial Services), Eos Advisory +7 more 9 investors	13.2	21	0%	66
▸	T-Cypher Bio Oxford · f. 2015 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2023-06-29	Borealis Ventures, Future Planet Capital +6 more 8 investors	24.3	42	—	64
▸	BIOS Health Cambridge · f. 2015 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator	Accelerate Cambridge, Allia Future Business Centre +32 more 34 investors	25.1	25	+38%	63
▸	Argonaute RNA Cardiff · f. 2015 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2026-02-26	Bristol Private Equity Club, CatSci +7 more 9 investors	6.8	8	—	62
▸	Metrion Biosciences Cambridge · f. 2015 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2023-12-04	Biomedical Catalyst, Eurostars +5 more 7 investors	9.6	40	+15%	61
▸	eXmoor Pharma Bristol · f. 2004 · Other Pharmaceuticals and Biotechnology	Therapeutic dev.	Near-clinical	Private Equity-Backed	PE Growth/Expansion 2023-05-30	Innovate UK, Kineticos Life Sciences Management +1 more 3 investors	51.7	71	0%	59
▸	Domainex Saffron Walden · f. 2001 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Secondary Transaction - Private 2019-01-17	Innovate UK, Juno Capital +6 more 8 investors	9.0	95	—	58
▸	Pencil Biosciences Macclesfield · f. 2018 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Seed Round 2023-10-01	Catapult Ventures, EMV Capital +10 more 12 investors	10.3	14	0%	56
▸	PharmEnable Therapeutics Cambridge · f. 2016 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC	Accelerate Cambridge, Andy Richards +21 more 23 investors	10.2	13	-45%	56
▸	Quotient Therapeutics London · f. 2022 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2022-04-12	Flagship Pioneering 1 investor	50.0	72	0%	56
▸	Fios Genomics Edinburgh · f. 2008 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2020-01-15	Archangel Investors, Charles River Laboratories International +3 more 5 investors	3.8	45	+5%	56
▸	Kinomica Macclesfield · f. 2016 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-07-24	Alderley Park, BGF (Financial Services) +9 more 11 investors	13.1	30	-86%	55
▸	Rathlin Therapeutics London · f. 2022 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2025-03-17	Columbus Venture Partners, Forbion +1 more 3 investors	26.6	4	—	55
▸	Pharmanovia Basildon · f. 2013 · Other Pharmaceuticals and Biotechnology	Therapeutic dev.	Near-clinical	Private Equity-Backed	Debt - General 2026-01-26	Triton Partners 1 investor	2264.4	338	-15%	55
▸	Sentinel Oncology Cambridge · f. 2005 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Grant 2020-06-01	Biomedical Catalyst, Cambridge Enterprise Ventures +4 more 6 investors	2.7	9	+78%	55
▸	DIOSynVax Hertford · f. 2017 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-12-24	Coalition for Epidemic Preparedness Innovations, Flu lab +5 more 7 investors	9.8	17	0%	53
▸	BioSure Waltham Abbey · f. 2011 · Pharmaceuticals	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Bankruptcy: Liquidation 2023-04-11	Energy Laboratory, Perscitus +1 more 3 investors	3.1	12	+114%	53
▸	Klona Biotech Oxford · f. 2025 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Seed Round	Arben Ventures, Draper Associates +4 more 6 investors	2.0	5	+156%	53
▸	Zentraxa Bristol · f. 2017 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Seed Round 2024-05-27	Bristol Private Equity Club, Elbow Beach Capital +14 more 16 investors	2.5	17	0%	53
▸	Rosemont Pharmaceuticals Leeds · f. 1967 · Pharmaceuticals	Review	Near-clinical	Private Equity-Backed	Continuation Fund Transaction 2025-05-15	—	10.4	283	-27%	52
▸	Alethiomics Oxford · f. 2021 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Seed Round 2021-12-15	Cancer Research Horizons, Oxford Science Enterprises +1 more 3 investors	8.0	11	0%	52
▸	ScreenIn3D Glasgow · f. 2018 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Seed Round 2025-06-12	Gabriel Investment Syndicate, Gabriel Investments +8 more 10 investors	1.3	7	0%	52
▸	CNX Therapeutics London · f. 1997 · Pharmaceuticals	Review	Near-clinical	Private Equity-Backed	Continuation Fund Transaction 2025-05-15	—	4.1	66	0%	52
▸	Isogenica Essex · f. 1998 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Grant 2021-10-01	Horizon 2020, Innovate UK +1 more 3 investors	6.3	23	0%	52
▸	Ubiquigent Dundee · f. 2009 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-12-12	Asterand Biosciences, Innovate UK +5 more 7 investors	1.7	6	+12%	52
▸	Sistemic Glasgow · f. 2007 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2020-04-10	ChimaeraBio, Highland Venture Capital +4 more 6 investors	3.9	7	0%	51
▸	Morvus Brecon · f. 2004 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2019-11-04	Cardiff University, FusionIP +2 more 4 investors	17.5	5	-63%	50
▸	Ingenza Penicuik · f. 2002 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-01-01	Horizon 2020, Innovate UK +4 more 6 investors	—	48	-5%	50
▸	ILC Therapeutics Glasgow · f. 2012 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-06-28	Eos Advisory, ILCT management +4 more 6 investors	13.1	8	—	49
▸	Medicines Management Solutions Leicester · f. 2007 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Private Equity-Backed	Buyout/LBO 2024-10-22	—	—	6	0%	49
▸	ConsoneAI Wetherby · f. 2020 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator 2024-12-01	BioIndustry Association, Change Makers +4 more 6 investors	0.5	4	+208%	49
▸	Ridge Pharma Reading · f. 2017 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Private Equity-Backed	PE Growth/Expansion 2018-09-07	Mercia Ventures, NVM Private Equity 2 investors	4.1	19	0%	49
▸	Mevox London · f. 2019 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2021-02-11	Kenneth Kelley, Morningside Group 2 investors	6.1	3	—	48
▸	MatchBio London · f. 2023 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Buyout/LBO 2024-01-01	Oxford Science Enterprises, University of Oxford 2 investors	—	10	0%	48
▸	Origin Peptides Linlithgow · f. 2018 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Grant 2025-11-18	General Inception, Pioneer Group +2 more 4 investors	0.4	9	+78%	47
▸	Biosynth Berkshire · f. 1966 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Private Equity-Backed	Buyout/LBO 2022-02-24	BroadOak Capital Partners, Kohlberg Kravis Roberts 2 investors	0.4	122	+174%	47
▸	Spliceor Cambridge · f. 2020 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Seed Round 2021-03-26	Accelerate Cambridge, Ajith Sukumaran +5 more 7 investors	0.7	6	—	46
▸	Iqur London · f. 2003 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2015-06-11	IP Group, IP Ventures +2 more 4 investors	3.9	14	-74%	46
▸	Aspire Pharma Petersfield · f. 2009 · Pharmaceuticals	Review	Near-clinical	Private Equity-Backed	Buyout/LBO 2021-09-24	H.I.G. Europe, PFR Ventures 2 investors	—	183	-12%	46
▸	MICA Biosystems Birmingham · f. 2010 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator	European Commission, Innovate UK +2 more 4 investors	1.5	8	0%	46
▸	Zoi Environmental Technologies London · f. 2012 · Biotechnology	Review	Near-clinical	Private Equity-Backed	Accelerator/Incubator	Pragma Capital Partners, Workup (Turkey) 2 investors	—	4	0%	46
▸	Amprologix Plymouth · f. 2018 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC	Ingenza, MassChallenge +4 more 6 investors	1.0	5	0%	46
▸	Heart Biotech Winchester · f. 2014 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-11-10	Innovate UK, MedTech Innovator +2 more 4 investors	6.4	5	0%	44
▸	ABBio Dundee · f. 2020 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC	Innova Partnerships 1 investor	—	3	0%	44
▸	Ryboquin Glasgow · f. 2013 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Secondary Transaction - Private 2021-11-01	Truetide 1 investor	4.5	1	0%	44
▸	Perfect Balance Truro · f. 2016 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2021-09-01	Medicxi 1 investor	—	2	0%	43
▸	CS Pharmaceuticals London · f. 2020 · Pharmaceuticals	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Secondary Transaction - Private	—	11.9	7	0%	43
▸	Defenition Harrogate · f. 2016 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Grant 2019-02-01	Innovate UK, IP Group +1 more 3 investors	0.5	—	—	43
▸	Natantis Edinburgh · f. — · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-12-26	Heriot-Watt University, Merck +3 more 5 investors	0.3	—	0%	42
▸	aTen Therapeutics Edinburgh · f. 2005 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Secondary Transaction - Private 2024-07-11	Innovate UK 1 investor	2.1	4	—	42
▸	Bitrobius Genetics Macclesfield · f. 2020 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2023-09-14	Catapult Ventures, Future Planet Capital +6 more 8 investors	2.1	5	0%	42
▸	AdoRx Therapeutics Edinburgh · f. 2017 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2018-06-20	Epidarex Capital, Sixth Element Capital 2 investors	5.0	3	-108%	42
▸	ReproGO Belfast · f. 2020 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC	College Green Ventures, ICURe +3 more 5 investors	0.5	2	—	42
▸	Forcefield Therapeutics London · f. 2020 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2024-03-28	Roche Venture Fund, Syncona 2 investors	8.4	8	0%	42
▸	Myomaker Bio London · f. 2023 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2026-01-28	ICURe, Loughborough University +1 more 3 investors	0.4	8	0%	42
▸	Talisman (Drug Discovery) Cambridge · f. 2013 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Grant 2019-03-01	Accelerate@Babraham, Innovate UK +2 more 4 investors	0.1	17	0%	41
▸	ET-traps Cambridge · f. 2015 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Seed Round 2022-01-06	Accelerate Cambridge, The Yope Foundation 2 investors	1.2	3	0%	41
▸	Eleven Therapeutics Cambridge · f. 2020 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Accelerator/Incubator	Entrée Capital, Gates Foundation +5 more 7 investors	22.0	31	0%	41
▸	Pronec Macclesfield · f. 2015 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Secondary Transaction - Private 2019-01-01	Catapult Ventures, Pxn Ventures 2 investors	0.4	—	—	41
▸	FabricNano London · f. 2018 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2022-03-03	Alexander Moscho, Arvind Gupta +18 more 20 investors	25.5	8	—	40
▸	Five Alarm Bio Cambridge · f. 2016 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Seed Round 2023-02-27	Cambridge Angels, Innovate UK +4 more 6 investors	0.9	3	—	39
▸	Anastasis Biotec London · f. 2016 · Biotechnology	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Equity Crowdfunding 2025-09-01	Innovate UK, Patha Capital 2 investors	0.4	4	0%	39
▸	Pebble Wilmslow · f. 2018 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2021-06-29	Catapult Ventures 1 investor	0.2	14	0%	38
▸	Evariste London · f. 2017 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Accelerator/Incubator 2024-01-01	BioIndustry Association, Change Makers 2 investors	7.9	9	0%	38
▸	BioAscent Motherwell · f. 2013 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-04-01	Maven Capital Partners UK, Pioneer Group 2 investors	2.1	77	-50%	36
▸	Blossom (Pharmaceuticals and Biotechnology) London · f. 2019 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2023-07-14	Deepbridge Capital 1 investor	2.5	59	0%	36
▸	Connexin Therapeutics York · f. 2018 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2021-07-01	Oxford Technology Management 1 investor	0.2	2	—	35
▸	Everna London · f. 2016 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC	Aera VC, Birgir Magnusson +7 more 9 investors	—	3	-313%	35
▸	iEthico Coventry · f. 2020 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator	Conduit Connect, Future Planet Capital +5 more 7 investors	2.4	8	0%	34
▸	Spirea Harrogate · f. 2015 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2022-05-18	Accelerate Cambridge, ACF Investors +12 more 14 investors	5.1	8	—	32
▸	Pheno Therapeutics Edinburgh · f. 2018 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2025-12-04	Advent Life Sciences, LifeArc Ventures +2 more 4 investors	6.2	8	0%	30
▸	Aston Particle Technologies Birmingham · f. 2016 · Pharmaceuticals	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator	Aston University, Aston University Endowment +5 more 7 investors	2.2	9	0%	30
▸	AtoCap London · f. 2011 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2026-02-26	Impact Planet Ventures, Mustard Seed + Partners +3 more 5 investors	2.1	4	0%	27
▸	CELEX Oncology London · f. 2016 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Accelerator/Incubator 2025-09-01	EIT Health, Grow London +1 more 3 investors	0.3	9	0%	26
▸	Vaccicure London · f. 2014 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Secondary Transaction - Private	—	4.2	8	0%	26
▸	Libero Pharma Edinburgh · f. 2018 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Early Stage VC 2022-01-01	Highland Venture Capital, TRICAPITAL Angel Investors 2 investors	3.1	5	—	26
▸	VascVersa Belfast · f. 2018 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Seed Round 2022-08-09	Clarendon Fund Managers, College Green Ventures +7 more 9 investors	1.2	6	0%	24
▸	GlykoGen Aberdeen · f. 2016 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Later Stage VC 2022-06-30	David Mason, Equity Gap +2 more 4 investors	1.0	2	0%	23
▸	Kairos Biotech Denbighshire · f. 2019 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2024-04-17	EchiumBio Holding, Myosotis Investments 2 investors	2.1	6	0%	23
▸	Singula Bio Oxford · f. 2020 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2022-06-01	Cancer Research Horizons, Oxford Science Enterprises +1 more 3 investors	2.6	8	0%	21
▸	Stratosvir Ingatestone · f. 2020 · Drug Discovery	Therapeutic dev.	Near-clinical	Venture Capital-Backed	Early Stage VC 2024-06-06	Cancer Research Horizons, Deep Science Ventures +3 more 5 investors	0.3	6	0%	21
▸	Bilitech Hitchin · f. 2017 · Biotechnology	Review	Near-clinical	Venture Capital-Backed	Early Stage VC	Cambridge Enterprise Ventures, University of Cambridge 2 investors	0.5	2	0%	19
▸	Genprice Potters Bar · f. 2015 · Other Pharmaceuticals and Biotechnology	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2021-05-20	Boyd Venture Challenge, Innov865 Alliance 2 investors	1.6	2	—	18
▸	Parkure Glasgow · f. 2014 · Drug Discovery	Review	Near-clinical	Venture Capital-Backed	Later Stage VC 2020-07-16	LAUNCH.ed, The Scottish Government +1 more 3 investors	0.3	3	-104%	8

★ Project Argonaut

The frozen top clinical-stage, VC/PE-backed shortlist — full research on each, with concerns flagged rather than deleted.

35 companies

1 Amber Therapeutics Implantable neuromodulation device — NOT a d…Didcot 94.3

▸

Target	Pudendal nerve (mixed urinary incontinence)
Modality	Implantable neuromodulation device — NOT a drug
Design	Fully implantable, adaptive sensor-driven neurostimulator (Picostim) that stimulates and monitors the pudendal nerve in real time
Mechanism	Closed-loop adaptive neuromodulation restoring bladder control; personalised stimulation responding to nerve signals

⚠ Flagged for review

Device, not a drug — Amber develops an implantable neuromodulation device for incontinence, not a pharmaceutical. Kept in Argonaut for now per instruction but flagged: does not fit a pure-therapeutics mandate.

Lead asset AMBER-UI. Strong data and raise (~£101M, NEA/F-Prime/Oxford Science Enterprises), but this is a medical device, not a therapeutic. Reclassified out of the main therapeutics screener.

Total raised£101M

Quality score94.3

Founded2020

HQ cityDidcot

Registered trials4

Employees45

Last financingAccelerator/Incubator

# investors12

Investors: 8VC, Biomedical Catalyst, Fidelity, F-Prime Capital, Intuitive Ventures, Lightstone Ventures, New Enterprise Associates, Oxford Science Enterprises, Queen Mary University of London, Setsquared Bristol, Tech Nation Group, University of Oxford

✎ Outreach notes

2 Ottimo Pharma Bifunctional antibody (biologic)Sandwich 89.1

▸

Target	PD-1 and VEGFR2 (dual)
Modality	Bifunctional antibody (biologic)
Design	Single bifunctional antibody (Jankistomig) combining PD-1 immune checkpoint blockade with VEGFR2 anti-angiogenic activity in one molecule
Mechanism	Simultaneously releases the immune brake (PD-1) and starves tumours of blood supply (VEGFR2) — combining two validated cancer mechanisms in one drug

CEO David Epstein (ex-Novartis Oncology / Seagen chair). ~£150M raised. First patient dosed early 2026. Founded 2020. One of the strongest profiles on the list.

Total raised£150M

Quality score89.1

Founded2017

HQ citySandwich

Registered trials1

Employees20

Last financingLater Stage VC

# investors11

Investors: Avoro Capital, Decheng Capital, Index Ventures, Janus Henderson Investors, JPMorgan Life Sciences Private Capital, Medicxi, OrbiMed, RTW Investments, Samsara BioCapital, The Invus Group, Yucca (Jersey)

✎ Outreach notes

3 Cumulus Oncology Small molecules — via an asset-creation 'hub…Edinburgh 86.1

▸

Target	Multiple oncology targets (PARG, GPR68, GTPases) via spinouts
Modality	Small molecules — via an asset-creation 'hub and spoke' model
Design	Company-creation studio: sources/de-risks oncology assets, then spins them into separate companies (Nodus Oncology — PARG inhibitor; GIO Therapeutics — GPR68/GPCRs; Modulus Oncology)
Mechanism	Precision oncology targeting molecularly-selected patient subgroups; AI/ML-guided target and asset prioritisation

CEO Clare Wareing. Founding team has taken ~17-18 oncology assets to approval. Structurally a step removed from being a single drug developer — it builds a portfolio of spinouts rather than one pipeline.

Total raised£69M

Quality score86.1

Founded2017

HQ cityEdinburgh

Registered trials—

Employees20

Last financingLater Stage VC

# investors7

Investors: Alba Equity, Apollo Informal Investment, Easton Group (United Kingdom), Eos Advisory, Mark Beaumont, Scottish Enterprise, The Scottish National Investment Bank

✎ Outreach notes

4 Sitryx Oral small moleculesOxford 85.3

▸

Target	Immunometabolism enzymes — PKM2, MTHFD2, SIK, itaconate pathway
Modality	Oral small molecules
Design	Lead SYX-5219 (oral PKM2 modulator, Phase 1, atopic dermatitis); SIT-047 (oral MTHFD2 inhibitor, psoriatic arthritis, clinic 2026); SYX-1042 (itaconate mimetic, partnered with Lilly, Phase 1)
Mechanism	Rebalances immune function by reprogramming the metabolism of disease-driving immune cells — aiming for biologic-like efficacy with oral dosing and disease remission rather than symptom control

Oxford, founded 2018, SV Health seed. ~$85M raised (SV, Sofinnova, OSE, Longwood, Lilly, GSK). Exclusive Lilly collaboration since 2020. World-class immunometabolism founders (Luke O'Neill, Jeff Rathmell et al).

Total raised£79M

Quality score85.3

Founded2016

HQ cityOxford

Registered trials1

Employees49

Last financingLater Stage VC

# investors6

Investors: GSK, Lilly USA, Longwood Fund, Oxford Science Enterprises, Sofinnova Partners, SV Health Investors

✎ Outreach notes

5 Mestag Therapeutics Agonist antibodies (biologics)Cambridge 83.2

▸

Target	Activated/pathogenic fibroblasts and fibroblast-immune interactions
Modality	Agonist antibodies (biologics)
Design	RAFT (Reversing Activated Fibroblast Technology) platform identifies targets; lead pipeline of first-in-class agonist antibodies. Phase 1 STARLYS study starting in cancer patients mid-2026
Mechanism	Interrupts fibroblast-mediated effects on immune cells in inflammatory disease and cancer — fibroblasts act as 'immune sentinels' driving disease

Cambridge, founded 2020. SV Health portfolio company. ~$40M financing March 2026. Major pharma deals: MSD ($1.9B collaboration), J&J licence. On the cusp of the clinic.

Total raised£89M

Quality score83.2

Founded2020

HQ cityCambridge

Registered trials1

Employees43

Last financingLater Stage VC

# investors6

Investors: Forbion, GV, Innovate UK, Johnson & Johnson JJDC, Northpond Ventures, SV Health Investors

✎ Outreach notes

6 Epitopea Off-the-shelf RNA immunotherapies / therapeu…Cambridge 78.5

▸

Target	Cryptigens — shared tumour-specific antigens from previously non-coding ('dark genome') DNA
Modality	Off-the-shelf RNA immunotherapies / therapeutic cancer vaccines
Design	Lead CryptiVax-1001 won MHRA approval April 2026 for first-in-human trial (ovarian cancer). CryptiMap platform identifies shared antigens across patients
Mechanism	Primes the immune system against 'Cryptigen' antigens shared across many patients with the same cancer — the shared nature is what makes an off-the-shelf (not personalised) product feasible

Cambridge + Montreal. CEO Alan Rigby (since July 2024; Jon Moore -> CSO). Merck deal up to $300M/product. Science from University of Montreal, Nature Cancer publication. Moving pre-clinical -> clinic now.

Total raised£44M

Quality score78.5

Founded2021

HQ cityCambridge

Registered trials1

Employees46

Last financingEarly Stage VC

# investors15

Investors: adMare Bioinnovations, Advent Life Sciences, BioIndustry Association, BIOQuébec, Cambridge Innovation Capital, CQDM, CTI Life Sciences Fund, Fonds de solidarite FTQ, Harrington Discovery Institute/University Health Holdings, Innovate UK, Investissement Quebec, IRICoR, Jonathan Milner, Meltwind Advisory, Novateur Ventures

✎ Outreach notes

7 Proveca Reformulated / repurposed small-molecule dru…Manchester 78.3

▸

Target	Paediatric formulations of established medicines
Modality	Reformulated / repurposed small-molecule drugs (specialty pharma)
Design	Converts adult medicines into properly-tested, child-appropriate formulations; regulatory + licensing model (e.g. Sialanar, Ceriday)
Mechanism	Not novel drug discovery — takes known actives and develops child-appropriate versions with proper trials, dosing and regulatory approval

Manchester, founded 2010. Revenue-oriented specialty pharma, closer to a commercial reformulation business than high-growth discovery biotech. Lower clinical risk, but different investment profile.

Total raised£19M

Quality score78.3

Founded2010

HQ cityManchester

Registered trials1

Employees74

Last financingLater Stage VC

# investors6

Investors: Albion Capital, AlbionVC, Catapult Ventures, Innovate UK, Kings Arms Yard VCT, Kreos Capital

✎ Outreach notes

8 Biosceptre Antibodies (topical + systemic) and a vaccineCambridge 71.4

▸

Target	nfP2X7 (non-functional P2X7 receptor — a cancer-specific conformation)
Modality	Antibodies (topical + systemic) and a vaccine
Design	Three candidates: BIL010t (topical antibody, Phase I basal cell carcinoma, positive early data); BIL03s (systemic antibody); BIL06v (vaccine). All target nfP2X7
Mechanism	Targets nfP2X7, a modified form of the P2X7 receptor expressed on cancer cells but not healthy tissue — enabling tumour-selective targeting across multiple modalities

Cambridge, founded 2004. CEO Gavin Currie; Nobel laureate Sir Greg Winter acting chairman. Raised £10M + £8.1M in 2025, so cash may be stronger than last-financing date suggests. IP-heavy.

Total raised£53M

Quality score71.4

Founded2004

HQ cityCambridge

Registered trials1

Employees16

Last financingLater Stage VC

# investors5

Investors: Innovate UK, Jungle Capital, McKenny-McFarlane Capital, Norcliffe Capital, Tuspark Science and Technology Service Group

✎ Outreach notes

9 Relation Therapeutics Small molecules / biologics (AI-discovered)London 70.9

▸

Target	Osteoporosis and complex-disease targets discovered from patient tissue
Modality	Small molecules / biologics (AI-discovered)
Design	'Lab-in-the-Loop' platform integrating human genetics, single-cell multi-omics, functional genomics and ML. Lead programme in osteoporosis; two trials
Mechanism	Uses AI to discover novel disease targets directly from human tissue, then develops its own medicines against them — the AI is the discovery engine, not the product

London, founded 2019. CEO David Roblin. GSK + Novartis deals. ~£168M raised (PitchBook) though public reporting nearer £80M. Genuine internal pipeline, not a software-for-hire model.

Total raised£168M

Quality score70.9

Founded2019

HQ cityLondon

Registered trials2

Employees131

Last financingLater Stage VC

# investors21

Investors: ARK Ventures (US), DCVC, Deerfield Management, Firstminute Capital, Foresite Capital, Gates Foundation, GSK, Hitachi Ventures, Jonathan Milner, Juvenescence, Khosla Ventures, Magnetic Ventures, Mark Stevenson, Meltwind Advisory, NVentures (Santa Clara), OMERS Ventures, Peer Schatz, Raptor Group, Realm Capital Ventures, Synergis Capital, Tech Nation Group

✎ Outreach notes

10 Causeway Therapeutics microRNA mimic (RNA therapeutic)Glasgow 67.1

▸

Target	microRNA-29a (miR-29a) — tendon disease
Modality	microRNA mimic (RNA therapeutic)
Design	Lead TenoMiR (CWT-001), a synthetic miR-29a mimic delivered by ultrasound-guided intratendinous injection. Positive Phase 2 (March 2026) in tennis elbow; advancing to Phase 3
Mechanism	Restores tendon structure and function by replacing lost miR-29a — aims to modify the disease at a molecular/structural level rather than just relieve pain (first disease-modifying tendon therapy)

Glasgow, founded 2015. CEO Declan Doogan. Phase 2 nuance: full ITT population missed primary pain endpoint; the positive result is in the correctly-injected subgroup, which needs addressing in Phase 3 design.

Total raised£23M

Quality score67.1

Founded2015

HQ cityGlasgow

Registered trials2

Employees7

Last financingLater Stage VC

# investors8

Investors: Declan Doogan, GU Holdings, Innovate UK, Mediqventures, Rahn+Bodmer, Scottish Enterprise, University of Glasgow, University of Glasgow Endowment

✎ Outreach notes

11 Theramex Established branded prescription medicines (…London 65.8

▸

Target	Women's health — menopause, osteoporosis, contraception, fertility, endometriosis
Modality	Established branded prescription medicines (specialty pharma) — ~50 products
Design	Commercial portfolio incl. Bijuva (HRT), Livogiva (teriparatide biosimilar, osteoporosis), Zoely, Seasonique, Intrarosa; in-licensing + acquisitions (e.g. Viatris women's health assets)
Mechanism	Commercialises and expands a broad portfolio of women's-health medicines — not novel discovery; PE-owned (PAI Partners + Carlyle since 2022)

London, roots from 1954. ~£1,279M raised (mostly debt/buyout financing). Large established specialty-pharma commercial business — very different profile from an early venture target.

Total raised£1,279M

Quality score65.8

Founded1954

HQ cityLondon

Registered trials14

Employees500

Last financingDebt Refinancing

# investors3

Investors: PAI Partners, Teva Pharmaceutical Industries, The Carlyle Group

✎ Outreach notes

12 Advanz Pharma Innovative medicines, specialty generics & b…London 65.3

▸

Target	Specialty, hospital and rare-disease indications (hepatology, GI, anti-infectives, critical care, endocrinology, oncology, CNS)
Modality	Innovative medicines, specialty generics & biosimilars, originator brands (~180-300 products)
Design	Global commercialisation platform; partners with biopharma to bring/enhance specialty and rare-disease medicines. Sales in 90+ countries
Mechanism	Acquires, develops, licenses and commercialises specialty/rare-disease medicines — a commercial-stage pharma, not early-stage discovery. PE-owned (Nordic Capital)

London, roots from 1963. ~£1,879M raised (mostly debt refinancing). Large established commercial pharma — included by the screen's industry code, but not a typical venture opportunity.

Total raised£1,879M

Quality score65.3

Founded1963

HQ cityLondon

Registered trials16

Employees717

Last financingDebt Refinancing

# investors—

Investors: —

✎ Outreach notes

13 BIOCAPTIVA Medical device — NOT a drugEdinburgh 64.6

▸

Target	Circulating free DNA (cfDNA) capture for cancer liquid biopsy
Modality	Medical device — NOT a drug
Design	BioCaptis device with proprietary msX polymer coatings, works alongside a standard apheresis machine to capture up to 100x more cfDNA than a blood draw. First-in-human trial run; US patent granted
Mechanism	Physically captures far larger quantities of cfDNA directly from blood to improve the sensitivity of downstream liquid-biopsy cancer tests — a sample-collection device, not a therapeutic

⚠ Flagged for review

Device / diagnostics, not a drug — BIOCAPTIVA makes a cfDNA capture device for liquid biopsy, not a therapeutic. Does not fit a pure-therapeutics mandate.

Edinburgh spinout (Univ. of Edinburgh), founded 2021. Backed by Archangels, Cancer Research Horizons, Scottish Enterprise. Explicitly a diagnostics/device company.

Total raised£8M

Quality score64.6

Founded2021

HQ cityEdinburgh

Registered trials1

Employees10

Last financingLater Stage VC

# investors7

Investors: Archangel Investors, British Business Investments, EverQuest Capital Partners, Old College Capital, Scottish Enterprise, The University of Edinburgh, University of Edinburgh Endowment

✎ Outreach notes

14 MiNA Therapeutics Small activating RNA (saRNA) therapeuticsLondon 64.2

▸

Target	Gene activation via small activating RNA (saRNA) — lead in liver cancer (CEBPA / MTL-CEBPA)
Modality	Small activating RNA (saRNA) therapeutics
Design	Lead MTL-CEBPA (upregulates CEBPA transcription factor) in liver cancer; broad saRNA pipeline. Multiple pharma collaborations
Mechanism	Pioneered saRNA — switches genes ON (upregulates expression), the mirror image of gene silencing — restoring protective proteins the body under-produces in disease

London, founded 2008. saRNA pioneer. Deals with Lilly, AstraZeneca, Boehringer Ingelheim, Servier. ~£116M raised. Genuine platform + internal pipeline.

Total raised£116M

Quality score64.2

Founded2008

HQ cityLondon

Registered trials3

Employees33

Last financingDebt - General

# investors6

Investors: aMoon Fund, Elliot Richmond, Galloway (Construction and Engineering), Innovate UK, Lilly USA, Nxera Pharma

✎ Outreach notes

15 Gylden Pharma Synthetic T cell-priming vaccines / immunoth…Abingdon 63.1

▸

Target	T cell-priming vaccines (infectious disease + cancer) + migraine (patch)
Modality	Synthetic T cell-priming vaccines / immunotherapies + microneedle patch drug delivery
Design	Vaccine candidates for dengue (naNO-DENGUE) and betacoronaviruses (naNO-COVID); personalised pancreatic cancer immunotherapy; migraine patch (via Zosano acquisition) seeking FDA marketing authorisation
Mechanism	Primes CD8 T cells against conserved antigens using synthetic non-biological peptide sets; nanoparticle + microneedle intradermal delivery avoids conventional needles

Abingdon. Renamed from Emergex Vaccines Oct 2024 (cross-check old records under either name). Broad pipeline across 3 areas (infectious disease, oncology, migraine); migraine patch is furthest along.

Total raised£53M

Quality score63.1

Founded2016

HQ cityAbingdon

Registered trials4

Employees36

Last financingLater Stage VC

# investors5

Investors: Cell Rising Capital, Innovate UK, Maiora Ventures, TAD Tech, Vickers Venture Partners

✎ Outreach notes

16 R1 Therapeutics Small molecule (phosphate-absorption blocker)London 60.3

▸

Target	Phosphate absorption (hyperphosphatemia in dialysis / kidney disease)
Modality	Small molecule (phosphate-absorption blocker)
Design	Lead programme blocking dietary phosphate absorption for dialysis patients; one registered trial
Mechanism	Blocks intestinal phosphate absorption to control hyperphosphatemia in chronic kidney disease / dialysis — addressing a common, serious problem in renal care

⚠ Flagged for review

Geography — R1 is listed as London but is actually based in Redwood City, California. A real, investable drug developer, but confirm it fits a UK-focused mandate.

PitchBook lists London but the company is actually based in Redwood City, California — geography flag for a UK-focused mandate. $77.5M Series A (Abingworth, F-Prime, DaVita). CEO Krishna Polu. Founded 2025.

Total raised£78M

Quality score60.3

Founded2025

HQ cityLondon

Registered trials1

Employees—

Last financingEarly Stage VC

# investors6

Investors: Abingworth, Curie.Bio, DaVita Venture Group, F-Prime Capital, SymBiosis (Bentonville), U.S. Renal Care

✎ Outreach notes

17 Mito.Tech Small molecule (mitochondria-targeted)London 60.2

▸

Target	Mitochondrial dysfunction / oxidative stress — SkQ1 (mild mitochondrial uncoupler)
Modality	Small molecule (mitochondria-targeted)
Design	Lead SkQ1; focus broadened from dry-eye (Visomitin) to obesity and MASH, incl. GLP-1 combination (27% weight loss in large-animal models); earlier work in neurodegeneration/autoimmune
Mechanism	Mild mitochondrial uncoupler that promotes lipid disposal and inhibits ferroptosis; increases energy expenditure and protects tissue from oxidative stress — positioned as a GLP-1 adjunct / follow-on

London, founded 2010. CEO Natalia Perekhvatova. Public positioning has shifted markedly from dry-eye to metabolic disease (obesity, MASH) — older descriptions are outdated.

Total raised£60M

Quality score60.2

Founded2010

HQ cityLondon

Registered trials3

Employees6

Last financingAccelerator/Incubator

# investors3

Investors: Essex Bio-technology, MSU Science Park, Rusnano

✎ Outreach notes

18 Celixir Cell and gene therapies (iMP cells, platelet…Stratford-upon-Avon 58.9

▸

Target	Heart failure, cancer and other conditions (cell & gene therapies)
Modality	Cell and gene therapies (iMP cells, platelet lysate, PML cells)
Design	Lead Heartcel/iMP cells for heart failure; other cell-therapy programmes
Mechanism	Immunomodulatory progenitor (iMP) cells intended to reduce scarring and promote repair in heart failure

⚠ Flagged for review

Integrity red flags — an independent investigation alleged fabricated data and misrepresented researcher affiliations, and the company was in serious financial distress before a rescue SPAC deal in 2023. Strong PitchBook numbers, but excluded from the Word-doc shortlist on integrity grounds. Handle with caution before any outreach.

Stratford-upon-Avon, founded 2009. Nobel-laureate co-founder (Sir Martin Evans).

Total raised£9M

Quality score58.9

Founded2009

HQ cityStratford-upon-Avon

Registered trials2

Employees8

Last financingLater Stage VC

# investors10

Investors: Angels 5K ( Specialized Finance), Ben Tibbits, Blueray Capital, Boundary Capital Partners, Maven Cognition, Plutus One Capital, Start-Up Chile, Swansea University, UK Innovation & Science Seed Fund, Víctor Massó

✎ Outreach notes

19 Helperby Therapeutics Antibiotic combination therapies ('resistanc…London 56.9

▸

Target	WHO critical-priority drug-resistant bacteria (Gram-negatives, MRSA)
Modality	Antibiotic combination therapies ('resistance breakers')
Design	Lead candidates combine an Antibiotic Resistance Breaker (ARB) — e.g. azidothymidine (AZT) — with an existing antibiotic (e.g. colistin) for drug-resistant UTIs; HT61 for decolonisation. Phase 1/2 data
Mechanism	'Resistance breakers' rejuvenate old antibiotics — combining an ARB with an existing drug restores or boosts activity against resistant bacteria and suppresses emergence of resistance

London, founded 2002. Spinout from St George's, Univ. of London (Prof Sir Anthony Coates). Only company developing new combinations of already-approved antimicrobials. AMR tailwinds but historically tough commercial field.

Total raised£11M

Quality score56.9

Founded2002

HQ cityLondon

Registered trials1

Employees6

Last financingGrant

# investors4

Investors: European Union, Kenelm Storey, Metellus, St. George's University of London

✎ Outreach notes

20 Almac Group CDMO / services (with a small Almac Discover…Craigavon 54.8

▸

Target	Contract drug discovery, development & manufacturing services
Modality	CDMO / services (with a small Almac Discovery internal arm)
Design	Integrated services across the drug lifecycle: discovery, API manufacture, clinical supply, commercial manufacture, diagnostics. Almac Discovery has internal assets (e.g. ALM-401)
Mechanism	Primarily a services business (CDMO) selling development and manufacturing to other pharma — not a venture-style drug developer

⚠ Flagged for review

CDMO / services company — Almac is primarily a contract development & manufacturing organisation (~7,900 staff), not a venture-stage drug developer. Has a small internal discovery arm, but does not fit a pure-therapeutics venture mandate.

Craigavon, founded 2002 (roots older). ~7,900 employees, privately owned by the McClay Foundation. Large established services company — flagged as a CDMO/services business, outside a pure-therapeutics thesis.

Total raised—

Quality score54.8

Founded2002

HQ cityCraigavon

Registered trials1

Employees7900

Last financingLater Stage VC

# investors3

Investors: Gates Foundation, QUBIS, Queen's University Belfast

✎ Outreach notes

21 Allergy Therapeutics (LON: AGY) Allergen-specific immunotherapy vaccines (SC…Worthing 54.8

▸

Target	Allergic disease — grass pollen, peanut, and other allergens
Modality	Allergen-specific immunotherapy vaccines (SCIT)
Design	Lead Grass MATA MPL (short-course subcutaneous immunotherapy, Phase III G306); uses MicroCrystalline Tyrosine (MCT) adsorbed allergoids + MPL adjuvant. ~27 trials
Mechanism	Short-course allergen-specific immunotherapy that retrains the immune system to tolerate allergens (shifts IgE/IgG4) — addressing the cause, not just symptoms; only six injections

⚠ Flagged for review

Publicly traded (LSE AIM: AGY) — Allergy Therapeutics is a listed company, so engagement would be via public markets rather than a private venture round. Worth noting as a different kind of opportunity.

Worthing, founded 1998. Publicly traded on LSE AIM (AGY) — so a public-markets play, not a typical private VC deal. Restructured/refinanced in recent years.

Total raised£72M

Quality score54.8

Founded1998

HQ cityWorthing

Registered trials27

Employees584

Last financingBuyout/LBO

# investors2

Investors: Fox Southern Holdings, ZQ Capital

✎ Outreach notes

22 Istesso Oral small moleculesLondon 53.9

▸

Target	Immunometabolism — programmed disease resolution (RA, MS, IPF)
Modality	Oral small molecules
Design	Lead MBS2320 (first-in-class disease-resolving agent), Phase 2b in rheumatoid arthritis (IST-06); leramistat and MBS2320 also in idiopathic pulmonary fibrosis. 5 trials
Mechanism	Dual mode of action — reduces inflammation AND supports remodelling/repair of damaged tissue — aiming to resolve underlying pathology (bone/joint), not just control symptoms

London. Immunometabolism, autoimmune/inflammatory focus. CEO Lisa Patel. Formerly linked to Modern Biosciences. Genuine clinical-stage small-molecule developer.

Total raised£13M

Quality score53.9

Founded—

HQ cityLondon

Registered trials5

Employees11

Last financingReverse Merger

# investors3

Investors: IP Group, Parkwalk Advisors, Puhua Capital

✎ Outreach notes

23 NeRRe Therapeutics Small-molecule receptor antagonistsStevenage 53.4

▸

Target	Neurokinin (NK-1/NK-3) receptors — neuronal hypersensitivity
Modality	Small-molecule receptor antagonists
Design	Retains orvepitant (NK-1 antagonist) for chronic cough; spun its lead NK-1/NK-3 asset into KaNDy Therapeutics -> acquired by Bayer -> elinzanetant, now FDA-approved as Lynkuet for menopausal hot flushes. 7 trials
Mechanism	Blocks neurokinin receptors to dampen the neuronal hypersensitivity driving conditions like chronic cough and vasomotor symptoms

Stevenage, founded 2012. CEO Mary Kerr. Low PitchBook scores understate it — already delivered a drug that Bayer acquired and the FDA approved (proven exit). Strong judgment call despite the model's low ranking.

Total raised£84M

Quality score53.4

Founded2012

HQ cityStevenage

Registered trials7

Employees11

Last financingLater Stage VC

# investors8

Investors: Advent Life Sciences, Columbus Venture Partners, Forbion, Fountain Healthcare Partners, Government of UK, GSK, Novo Holdings, OrbiMed

✎ Outreach notes

24 veMico Small molecules (AI + synthetic biology disc…Worthing 52.7

▸

Target	Ageing / senescence pathways ('healthy ageing')
Modality	Small molecules (AI + synthetic biology discovery)
Design	Uses AI and synthetic biology to identify and advance candidates that slow ageing processes; earlier-stage pipeline. 2 trials
Mechanism	Targets biological drivers of ageing to extend healthy lifespan (healthspan) — an emerging, less-validated therapeutic area

Worthing, founded 2018. Anti-ageing/longevity focus. Note: longevity is a scientifically ambitious, harder-to-validate area — clinical endpoints for 'ageing' are not yet regulatory-standard.

Total raised£33M

Quality score52.7

Founded2018

HQ cityWorthing

Registered trials2

Employees5

Last financingSeed Round

# investors1

Investors: SOSV

✎ Outreach notes

25 Sitala Bio Anti-inflammatory medicines (small molecules…Cambridge 52.6

▸

Target	Neurodegeneration and cancer — toxin/protein clearance in the brain
Modality	Anti-inflammatory medicines (small molecules / biologics)
Design	Develops medicines targeting removal of toxins/pathogenic proteins from the brain; early clinical stage. 2 trials
Mechanism	Aims to clear disease-driving toxins/proteins from the CNS to treat neurodegenerative disease and cancer

Cambridge, founded 2021. Early-stage. Limited public pipeline detail — worth direct diligence to pin down the lead asset and mechanism precisely.

Total raised£7M

Quality score52.6

Founded2021

HQ cityCambridge

Registered trials2

Employees10

Last financingPE Growth/Expansion

# investors4

Investors: Forbion, MaasInvest, OrbiMed, Shake It Up Australia Foundation

✎ Outreach notes

26 Viramal Drug delivery / reformulated therapies (incl…London 51.3

▸

Target	Women's health — fertility, menopause (HRT), contraception, vaginal health
Modality	Drug delivery / reformulated therapies (incl. progesterone gel)
Design	Lead is a topical/vaginal progesterone gel and related women's-health formulations; drug-delivery technology (Vergel). 3 trials
Mechanism	Improved delivery of established actives (e.g. progesterone) for women's-health indications — more a delivery/reformulation play than novel discovery

London, founded 2013. Women's health, delivery-focused. Confirm how much is novel drug vs delivery technology before positioning as a pure therapeutic.

Total raised£9M

Quality score51.3

Founded2013

HQ cityLondon

Registered trials3

Employees15

Last financingAccelerator/Incubator

# investors2

Investors: Medeon Science Park, NCL Technology Ventures

✎ Outreach notes

27 Circadian Therapeutics Small-molecule drugs AND a home diagnostic E…Oxford 49.6

▸

Target	Circadian-rhythm biology — serious diseases linked to clock disruption
Modality	Small-molecule drugs AND a home diagnostic EEG device (dual mission)
Design	Own materials describe both drug candidates and a home-based ambulatory EEG diagnostic device; IP from Oxford Nuffield Dept of Clinical Neurosciences. 1 trial
Mechanism	Modulates circadian rhythms to treat physiological/pathological conditions; the diagnostic arm measures brain function/circadian markers at home

⚠ Flagged for review

Device + drug hybrid, unclear live drug — Circadian's own description splits its mission between drug candidates and a home diagnostic EEG device, and no named drug candidate appears to have advanced since its 2016 launch (last financing 2020). Was cut from the Word-doc shortlist for this reason; flagged rather than removed.

Oxford spinout, founded 2016. Last disclosed financing Feb 2020, backed by Oxford Science Enterprises. Could not confirm a named drug candidate has advanced since 2016.

Total raised£8M

Quality score49.6

Founded2016

HQ cityOxford

Registered trials1

Employees5

Last financingEarly Stage VC

# investors2

Investors: Oxford Science Enterprises, University of Oxford

✎ Outreach notes

28 SEEK (Drug Discovery) Small molecules + vaccines (multi-asset)London 45.8

▸

Target	Broad — flu vaccine, pain, and other unmet needs (multiple programmes)
Modality	Small molecules + vaccines (multi-asset)
Design	Portfolio incl. FLU-v (universal influenza vaccine) and other candidates; spins assets into ventures (e.g. hVIVO/Imutex links). 6 trials
Mechanism	Diverse pipeline; FLU-v aims for broad, durable T-cell-based influenza protection across strains

London, founded 2004. Multi-asset discovery group with a spin-out model. Broad but somewhat diffuse pipeline — worth pinning down which asset is the current lead before outreach.

Total raised£4M

Quality score45.8

Founded2004

HQ cityLondon

Registered trials6

Employees9

Last financingSecondary Transaction - Private

# investors—

Investors: —

✎ Outreach notes

29 Haoma Medica Oral small molecule (NaQuinate)London 44.5

▸

Target	Bone — osteoporosis and osteopenia
Modality	Oral small molecule (NaQuinate)
Design	Lead NaQuinate (a naphthoquinone carboxylic acid; synthetic vitamin K2/menaquinone derivative), marketed concept 'Osteopura'. First-in-human trial completed. 1 trial
Mechanism	Regulates BOTH bone build-up and breakdown (unlike existing drugs that hit only one side); synergises with mechanical loading to build cortical bone mass — dual-action with a clean safety profile

London, founded 2009. Developed at Royal Veterinary College (Prof Stephen Hodges). Small raise (~£3.6M). Also has a nutraceutical subsidiary (PuraLife) — confirm pharma vs nutraceutical split.

Total raised£4M

Quality score44.5

Founded2009

HQ cityLondon

Registered trials1

Employees5

Last financingLater Stage VC

# investors1

Investors: Silkweed Limited

✎ Outreach notes

30 Mundipharma International Established branded medicines (specialty pha…Cambridge 41.9

▸

Target	Pain, respiratory, oncology, anti-infectives, CNS
Modality	Established branded medicines (specialty pharma)
Design	Large commercial portfolio across multiple therapeutic areas; 77 registered trials. Global network of independent associated companies
Mechanism	Commercialises and develops established medicines — a large commercial pharma, not early-stage discovery

⚠ Flagged for review

Large established pharma — Mundipharma is a multi-decade commercial pharmaceutical network (77 trials on file), not an early-stage venture target. Also carries historical reputational baggage (opioid-related, via the wider Purdue/Sackler-linked network) worth awareness.

Cambridge, roots from 1952. Very large established pharma (Purdue-linked network, historically associated with opioid controversies in the US — worth awareness). Not a typical venture opportunity.

Total raised—

Quality score41.9

Founded1952

HQ cityCambridge

Registered trials77

Employees—

Last financingPE Growth/Expansion

# investors1

Investors: NovaQuest Capital Management

✎ Outreach notes

31 Persica Pharmaceuticals Small-molecule antibiotic (intradiscal formu…Canterbury 38.3

▸

Target	Chronic low back pain (cLBP) with Modic Type 1 changes — bacterial disc infection
Modality	Small-molecule antibiotic (intradiscal formulation)
Design	Lead PP353 (intradiscal linezolid + iohexol + thermosensitive gel), injected under image guidance into the disc. Positive Phase 1b (Lancet eClinicalMedicine, 2026); advancing to registrational studies
Mechanism	Treats the underlying bacterial infection causing a subset of chronic low back pain — a targeted, non-opioid, cause-directed therapy rather than symptom relief

Canterbury/London, founded 2013. Non-opioid pain angle is attractive given opioid concerns. Note: the 'infection causes back pain' thesis is scientifically contested by some clinicians — worth understanding the debate.

Total raised£24M

Quality score38.3

Founded2013

HQ cityCanterbury

Registered trials1

Employees8

Last financingLater Stage VC

# investors1

Investors: Nebbegård Invest

✎ Outreach notes

32 Aelius Biotech Research tools / testing services — NOT a drugNewcastle upon Tyne 36.9

▸

Target	Oral drug development testing (model gut system)
Modality	Research tools / testing services — NOT a drug
Design	'Model gut' in vitro/in vivo system simulating digestion, mucus permeation and epithelial absorption; testing services + human trials for orally-delivered products. 1 trial
Mechanism	Provides a physiological gut model to de-risk orally-delivered products — a tools/services business supporting other developers, not a therapeutic itself

⚠ Flagged for review

Tools / testing services, not a drug — Aelius provides a 'model gut' testing system and services to other developers, not its own therapeutic. Does not fit a pure-therapeutics mandate.

Newcastle, founded 2018. Very small (~£2.5M raised). Genuinely a tools/testing company (model gut) rather than a drug developer.

Total raised£3M

Quality score36.9

Founded2018

HQ cityNewcastle upon Tyne

Registered trials1

Employees18

Last financingLater Stage VC

# investors6

Investors: European Regional Development Fund (Brandenburg), Innovate UK, Mercia Ventures, NEDFi Venture Capital, Newcastle University, North East Fund

✎ Outreach notes

33 Ferryx Live biotherapeutics (bacterial products)Bristol 35.9

▸

Target	Gastrointestinal inflammation — IBD / IBS
Modality	Live biotherapeutics (bacterial products)
Design	Develops safe/effective bacterial products to prevent and treat GI inflammation incl. IBD and IBS. Early clinical. 1 trial
Mechanism	Live biotherapeutic bacteria that modulate the gut to prevent/treat inflammation — a natural alternative to traditional drugs

Bristol, founded 2019. Very early and small (~£1M raised). Note description mentions 'humans and animals' — confirm the human-therapeutic focus vs any veterinary component before positioning.

Total raised£1M

Quality score35.9

Founded2019

HQ cityBristol

Registered trials1

Employees5

Last financingSeed Round

# investors8

Investors: Deepbridge Capital, EIT Food, Evenlode Foundation, Innovate UK, LYVA Labs, Setsquared Bristol, University of Bristol, University of Cambridge

✎ Outreach notes

34 Aurum Biosciences Oxygen-carrying perfluorocarbon (PFC) emulsi…Glasgow 32.2

▸

Target	Acute ischaemic stroke (and spinal cord injury, inflammation)
Modality	Oxygen-carrying perfluorocarbon (PFC) emulsion — therapeutic + diagnostic
Design	Lead ABL-101 (emulsified perfluorocarbon, IV). Completed early Phase 1/2a; planned Phase 2a in stroke, spinal cord injury and inflammation imaging. Also a 19F-MRI diagnostic use
Mechanism	PFC carries and delivers oxygen independent of haemoglobin — oxygenating tissue beyond the stroke clot to protect the at-risk 'penumbra'; doubles as an MRI imaging marker

Glasgow, founded 2010. CSO/inventor Dr Celestine Santosh. Small raise (~£3.75M). Dual therapeutic + diagnostic use of ABL-101 — confirm which is the primary commercial path.

Total raised£4M

Quality score32.2

Founded2010

HQ cityGlasgow

Registered trials1

Employees7

Last financingLater Stage VC

# investors6

Investors: Infinion Biopharma, InnoScot Health, Scottish Enterprise, TRICAPITAL Angel Investors, University of Glasgow, Wellcome Trust

✎ Outreach notes

35 Biotherapy Services Autologous cell therapiesLondon 20.5

▸

Target	Complex/chronic wounds
Modality	Autologous cell therapies
Design	Develops autologous (patient-derived) therapies for wound healing and complex chronic wounds. Early stage. 1 trial
Mechanism	Uses the patient's own cells to promote healing of chronic wounds

London, founded 2013. Very early and small (~£6M raised), lowest quality score on the list. Limited public detail — worth direct diligence to confirm the lead product and stage.

Total raised£6M

Quality score20.5

Founded2013

HQ cityLondon

Registered trials1

Employees5

Last financingPE Growth/Expansion

# investors1

Investors: Foresight Group

✎ Outreach notes

Project Asclepius

Near-clinical therapeutic and review companies

109 companies

1 CHARM Therapeutics Review (unclear)London 93.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a deep learning platform intended to deliver medicines of transformational efficacy for patients. The company platform delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies, enabling doctors to treat undruggable disease targets with an advanced approach to create life-changing therapies for patients.

Total raised£150M

Quality score93.5

Founded2021

HQ cityLondon

Registered trials—

Employees53

Last financingEarly Stage VC

# investors16

Investors: Axial (San Francisco), Braavos Investment Advisers, Bristol-Myers Squibb, Dhyan, F-Prime Capital, General Catalyst, Grep VC, Jacob Goodwin, Khosla Ventures, Kohlmann, New Enterprise Associates, NVentures (Santa Clara), Nvidia, OrbiMed, Sahsen Ventures, SR One Capital Management

✎ Outreach notes

2 Maxion Therapeutics Review (unclear)Cambridge 90.0

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a novel platform designed to generate antibody-like therapeutics to solve ion channel and GPCR-driven diseases. The company combines mini-proteins found in venom and other sources called knottins into the antibody surface to create mixtures while creating the optimum drug-like properties of antibodies, enabling patients with chronic pain, autoimmune, and cardiovascular diseases to access safe, long-lasting, and selective treatments.

Total raised£105M

Quality score90.0

Founded2020

HQ cityCambridge

Registered trials—

Employees50

Last financingLater Stage VC

# investors8

Investors: BGF (Financial Services), British Business Bank, General Catalyst, Innovate UK, LifeArc Ventures, Lilly USA, Monograph Capital, Solasta Ventures

✎ Outreach notes

3 bit.bio Review (unclear)Cambridge 88.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a synthetic biology platform designed to accelerate research, drug discovery, and cell therapy development through engineered human cell production. The company offers induced pluripotent stem cell-derived cells, proprietary gene-targeting technology, datasets, and research services, enabling biotechnology companies, pharmaceutical companies, and research institutions to improve disease modeling, train AI models, reduce development costs, and expand cell therapy applications.

Total raised£234M

Quality score88.5

Founded2016

HQ cityCambridge

Registered trials—

Employees164

Last financingLater Stage VC

# investors34

Investors: ARCH Venture Partners, BlueYard Capital, Cambridge Enterprise Ventures, Charles River Laboratories International, Charles Songhurst, Corastone (Financial Software), Darrin Disley, Dynamk Capital, Firstminute Capital, Foresite Capital, Good AI Capital, Harmonix Fund, Hawktail, Innovate UK, Jochen Kleinknecht, Jonathan Milner, L1 Group, M&G, Meltwind Advisory, Metaplanet Holdings, Milad Alucozai, Milky Way Research Foundation, Nikolaus Starzacher, Puhua Capital, QUAD Investment Management, Resilience (Blue Ash), Richard Klausner, Skaala, Stemar Capital, Tech Nation Group, Tencent Holdings, University of Cambridge, Verition Fund Management, Weslie Janeway

✎ Outreach notes

4 Laverock Therapeutics Review (unclear)London 84.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a gene silencing platform designed to create programmable therapies for complex diseases. The company offers recoded microRNA-based gene control technology and therapeutic development capabilities, enabling biotechnology and healthcare organizations to develop targeted therapies with controlled gene expression and improved safety profiles.

Total raised£28M

Quality score84.3

Founded2021

HQ cityLondon

Registered trials—

Employees29

Last financingAccelerator/Incubator

# investors13

Investors: Agronomics, Calculus Capital, Emerald Technology Ventures, Eos Advisory, Future Planet Capital, Grow London, Innovate UK, Lilly USA, Maven Capital Partners UK, Mercia Ventures, Norcliffe Capital, Tekfen Ventures, UK Innovation & Science Seed Fund

✎ Outreach notes

5 NeoPhore Therapeutic developerAltrincham 83.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of novel small molecule therapies designed to treat cancer through stimulation of the immune system. The company's therapies target genetic mechanisms to create neoantigen which are known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Total raised£69M

Quality score83.7

Founded2017

HQ cityAltrincham

Registered trials—

Employees20

Last financingLater Stage VC

# investors21

Investors: 3B Future Health Fund, 4basebio, Astellas Venture Management, Bristol-Myers Squibb, Cambridge Enterprise Ventures, Claris Ventures, Club degli investitori, I2I Capitals, Innovate UK, InvestAG, Italian Angels for Growth, Landmark Capital (Italy), LIFTT, Meltwind Advisory, NEVA SGR, O2h Ventures, Parkwalk Advisors, Sixth Element Capital, Syndicate, University of Cambridge, University of Turin

✎ Outreach notes

6 NRG Therapeutics Review (unclear)Stevenage 82.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function. The company's platform aims to make novel medicines that act through the preservation of mitochondrial function for the treatment and stopping the progression of neurodegenerative diseases, enabling physicians to treat patients with chronic disorders effectively.

Total raised£95M

Quality score82.7

Founded2018

HQ cityStevenage

Registered trials—

Employees7

Last financingLater Stage VC

# investors17

Investors: Arthur Roach, Brandon Biocatalyst, Brandon Capital, British Business Bank, Caixa Capital Risc, Claudio Nessi, Criteria Bio Ventures, Francesco Draetta, Innovate UK, Katherine Jackman, M Ventures, Michael J. Fox Foundation, Novartis Venture Fund, Omega Funds, Parkinson's UK, SV Health Investors, UK Government's Biomedical Catalyst funding

✎ Outreach notes

7 Orbit Discovery Review (unclear)Oxford 82.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of peptide discovery services designed to deliver novel, functional, and biologically relevant peptide therapeutic hits. The company's platform leverages a peptide bead display technology, enabling the identification of peptides for radiopharmaceuticals, nucleic acid targeting, and the identification of GPCR agonists and antagonists.

Total raised£16M

Quality score82.5

Founded—

HQ cityOxford

Registered trials—

Employees31

Last financingLater Stage VC

# investors10

Investors: Borealis Ventures, Future Planet Capital, Innovate UK, Kapil Joory, Oxford Investment Consultants, Oxford Science Enterprises, Oxford Technology Management, Oxford University Innovation, Perivoli Innovations, University of Oxford

✎ Outreach notes

8 Curve Therapeutics Therapeutic developerSouthampton 81.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a drug discovery platform designed to develop a pipeline of therapeutics for cancer. The company's platform transforms the discovery of new therapeutics through direct functional screening of genetically encoded microcycle libraries against targets in their native environment, enabling patients to get a cure against several challenging cancer targets, including intracellular protein-protein and protein-gene interactions.

Total raised£57M

Quality score81.6

Founded2019

HQ citySouthampton

Registered trials—

Employees39

Last financingLater Stage VC

# investors6

Investors: Advent Life Sciences, British Business Bank, Columbus Venture Partners, Epidarex Capital, Pfizer Ventures, University of Southampton

✎ Outreach notes

9 AstronauTx Review (unclear)London 81.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology company intended to improve the treatment of Alzheimer's disease and other neurodegenerative diseases. The company specializes in developing new medicines in order to restore the normal behavior of astrocyte patients, enabling healthcare professionals to effectively treat neurotoxicity in the brain caused by dementia.

Total raised£69M

Quality score81.5

Founded2019

HQ cityLondon

Registered trials—

Employees10

Last financingEarly Stage VC

# investors9

Investors: Brandon Capital, Bristol-Myers Squibb, EQT Life Sciences, Future Fund (UK), MPM BioImpact, Novartis Venture Fund, SV Health Investors, UCL Technology Fund, University College London

✎ Outreach notes

10 Ogibiotec Review (unclear)Edinburgh 78.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a modular culturing system intended to replicate manual flask culturing. The company's system provides a base unit and retrofittable modules that can be added or removed by the customer at any point ensuring maximum adaptability mid-experiment, enabling scientists to select the measurement and control features they require for their culturing process.

Total raised£5M

Quality score78.8

Founded2019

HQ cityEdinburgh

Registered trials—

Employees15

Last financingLater Stage VC

# investors13

Investors: Andrew Coleman, Apollo Informal Investment, Converge Challenge, G & S Buttsworth Holdings, Higgs Centre for Innovation, ICURe, Merleview Capital, Old College Capital, QUBIS, Sapphire Capital Partners, Scottish Enterprise, TRICAPITAL Angel Investors, WCS Nominees

✎ Outreach notes

11 Enara Bio Review (unclear)Oxford 78.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of medical drug vaccines and other immunotherapy technology designed to treat cancer. The company's technology allows hospitals to identify and assess their tumor-specificity and immunogenic potential based on antigens derived from endogenous retroviral (ERV) DNA sequences, enabling the healthcare industry to monitor and combat cancer efficiently.

Total raised£83M

Quality score78.7

Founded2016

HQ cityOxford

Registered trials—

Employees63

Last financingLater Stage VC

# investors7

Investors: Blackwells Capital, M Ventures, Pfizer Ventures, RA Capital Management, Samsara BioCapital, SV Health Investors, The Francis Crick Institute

✎ Outreach notes

12 Axol Bioscience Therapeutic developerRoslin 78.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology company intended for medical research, disease modeling, and drug development. The company generates stem cells from blood and tissue cells, extracted from healthy and diseased patients, to develop the best human cell biology research tools, which can advance medical research and drug discovery for many of the world's biggest and best-known pharma companies and research institutions, enabling researchers to develop treatments based on stem cell research.

Total raised£20M

Quality score78.5

Founded2013

HQ cityRoslin

Registered trials—

Employees46

Last financingLater Stage VC

# investors13

Investors: Amadeus Capital Partners, BroadOak Capital Partners, Calculus Capital, Cambridge Angels, Cleevely & Partners, Darrin Disley, EMV Capital, Jonathan Milner, Martlet Capital, Meltwind Advisory, Roslin Foundation, Scottish Enterprise, SyndicateRoom

✎ Outreach notes

13 Mosaic Therapeutics Therapeutic developerLondon 74.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of an oncology therapeutics company intended to tackle cancers with substantial unmet needs. The company utilizes artificial intelligence to prioritize key anti-cancer targets and to genetically identify those patient groups most likely to respond to treatments developed against those targets by using next-generation tumor systems and advanced genomic technologies, enabling patients to treat cancers based on their tissue of origin.

Total raised£39M

Quality score74.4

Founded2020

HQ cityLondon

Registered trials—

Employees26

Last financingLater Stage VC

# investors6

Investors: Accelerate@Babraham, Cambridge Innovation Capital, Cancer Research Horizons, Innovate UK, Syncona, Wellcome Trust

✎ Outreach notes

14 Locate Bio Review (unclear)Nottingham 73.2

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a regenerative medicine platform designed to help surgeons restore patients' lives through research, innovation, and performance. The company's platform develops thermally activated and injectable scaffolds that solidify within the body and can be used to support tissue growth before degrading away, enabling pharmaceutical delivery, medical devices, and biotechnology companies to provide advanced delivery systems and regenerative matrices.

Total raised£37M

Quality score73.2

Founded2001

HQ cityNottingham

Registered trials—

Employees26

Last financingLater Stage VC

# investors7

Investors: BGF (Financial Services), Heraeus Holding, Innovate UK, Mercia Asset Management, Mercia Ventures, University of Nottingham, Wellcome Trust

✎ Outreach notes

15 Adendra Therapeutic developerLondon 70.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of therapeutics designed to build on new insights into dendritic cell biology. The company specializes in discovering and developing new medicines for the treatment of cancers and autoimmune diseases based on insights into the biology of dendritic cells and their ability to cross-present antigens, enabling the healthcare sector to cure cancer efficiently.

Total raised£54M

Quality score70.3

Founded2021

HQ cityLondon

Registered trials—

Employees3

Last financingEarly Stage VC

# investors3

Investors: Apple Tree Partners (ATP), Cancer Research Horizons, The Francis Crick Institute

✎ Outreach notes

16 Jellagen Review (unclear)Cardiff 70.0

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of collagen products designed to address complex tissue engineering and regenerative medical needs. The company's products offer non-mammalian jellyfish collagen ranging from in-vitro to in-vivo applications, as well as a batch-to-batch consistency offering advantages to research and medical applications, enabling medicinal researchers to conduct in-house research and development and supporting the fabrication of new medical devices offering new approaches to wound management and tissue engineering.

Total raised£24M

Quality score70.0

Founded2013

HQ cityCardiff

Registered trials—

Employees13

Last financingLater Stage VC

# investors11

Investors: Angels Invest Wales, Cardiff Capital Region, Collagen Solutions, Development Bank of Wales, Innovate UK, London Business Angels, Maven Cognition, MedCity, Newable Partnership, Thai Union Group, Xénos

✎ Outreach notes

17 Amphista Therapeutics Therapeutic developerCambridge 69.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of next-generation targeted protein degradation therapeutics designed to treat a range of diseases. The company's therapeutics advance novel approaches in targeted protein degradation to create a new generation of therapies with improved efficacy and identify the cell's degradation machinery to modulate the abundance of proteins that are responsible for disease progression, enabling healthcare providers to improve the lives of patients.

Total raised£78M

Quality score69.8

Founded2017

HQ cityCambridge

Registered trials—

Employees65

Last financingLater Stage VC

# investors9

Investors: Advent Life Sciences, Eli Lilly and Company Foundation, Forbion, Gilde Healthcare, Novartis Venture Fund, Pioneer Group, Scottish Enterprise, SV Health Investors, University of Dundee

✎ Outreach notes

18 Endlyz Therapeutics Therapeutic developerLondon 69.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of disease-modifying therapeutics designed to restore endo-lysosomal function and abrogate neurodegeneration. The company specializes in developing technology that restores endo-lysosomal function and abrogates neurodegeneration in Parkinson's disease (PD) and other dementias, enabling patients to prevent the disease in the early stages.

Total raised£23M

Quality score69.6

Founded2021

HQ cityLondon

Registered trials—

Employees7

Last financingSeed Round

# investors7

Investors: AbbVie Ventures, BioIndustry Association, CD3 Leuven, Oxford Science Enterprises, Parkinson's UK, SV Health Investors, University of Oxford

✎ Outreach notes

19 Sortera Bio Review (unclear)Cambridge 68.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biologics discovery platform intended to accelerate drug development through Artificial Intelligence (AI) powered screening technology. The company leverages its Deep Screening platform to generate extensive sequence-function datasets from individual experiments, addressing the data scarcity issue that hinders machine learning model training for novel biologics design, enabling pharmaceutical partners to unlock therapeutic leads, irrespective of their starting point or target complexity.

Total raised£20M

Quality score68.1

Founded2023

HQ cityCambridge

Registered trials—

Employees20

Last financingEarly Stage VC

# investors3

Investors: AstraZeneca, BioNTech, Cambridge Innovation Capital

✎ Outreach notes

20 Carbometrics Review (unclear)Bristol 67.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a synthetic glucose-binding molecule designed for glucose sensing applications. The company's technology is a selective synthetic receptor for glucose that is produced through a streamlined and scalable synthesis, exhibiting robustness against high temperatures, prolonged solution exposure, extreme pH levels, and steam sterilization, enabling healthcare professionals to develop advanced glucose detection methods for various uses.

Total raised£14M

Quality score67.8

Founded2018

HQ cityBristol

Registered trials—

Employees18

Last financingAccelerator/Incubator

# investors10

Investors: Ada Ventures, Change Makers, Incubateur Telecom Paris, MiniMed Group, Parkwalk Advisors, Science Creates, SCVC, Selvedge Venture, University of Bristol, University of Bristol Endowment

✎ Outreach notes

21 CardiaTec Therapeutic developerCambridge 67.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of an artificial intelligence (AI) drug target discovery company intended to transform the biology behind cardiovascular disease. The company develops a target identification and novel drug discovery platform to deliver therapeutics for cardiovascular diseases, enabling healthcare professionals to address the unmet needs surrounding CAD diagnostics, patient stratification, and therapeutics.

Total raised£8M

Quality score67.7

Founded2021

HQ cityCambridge

Registered trials—

Employees17

Last financingLater Stage VC

# investors18

Investors: APEX Ventures, Ascension (Private Equity), Cambridge Angels, Cambridge Enterprise Ventures, Cambridge University Entrepreneurs, Continuum Health Ventures, Crista Galli Ventures, Elevation Capital (Canada), Laidlaw Scholars Ventures, LQD VC, Maximilien Levesque, Montage Ventures, Naheed Kurji, O2h Ventures, Panacea Capital, Plug and Play Tech Center, The Francis Crick Institute, University of Cambridge

✎ Outreach notes

22 Clock.bio Review (unclear)Cambridge 67.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a stem cell research firm intended to extend and improve the standard of living by reversing the harmful effects of time in cells. The company specializes in developing novel treatments that can prevent and treat age-related diseases and decode the rejuvenation programs present in human cells to increase human healthspan, enabling humans to utilize regenerative capabilities.

Total raised£10M

Quality score67.4

Founded2020

HQ cityCambridge

Registered trials—

Employees10

Last financingAccelerator/Incubator

# investors7

Investors: BlueYard Capital, Firstminute Capital, Frame Shift Bio-Incubator, Jonathan Milner, Meltwind Advisory, Onsight Ventures, Phoenix Court

✎ Outreach notes

23 Kuano Review (unclear)Cambridge 66.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a quantum mapping and AI-based discovery platform designed to offer assistance for drug discovery and design. The company's platform combines quantum physics, AI, and medicinal chemistry in a unique approach to transforming the discovery of therapeutics focused on enzyme inhibition, enabling drug developers to improve the quality of new drugs being produced, as well as reducing discovery time.

Total raised£4M

Quality score66.7

Founded2020

HQ cityCambridge

Registered trials—

Employees12

Last financingAccelerator/Incubator

# investors18

Investors: ACF Investors, AI Seed, Ascension (Private Equity), Beresford Ventures, BioIndustry Association, Cambridge Angels, Creative Destruction Lab, Entrepreneurs First, Innovate UK, Meltwind Advisory, Mercia Asset Management, Mercia Ventures, O2h Ventures, Science Creates, Stevenage Bioscience Catalyst, SyndicateRoom, University of Toronto, Wren Investment Office

✎ Outreach notes

24 SiSaf Review (unclear)Guildford 66.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a biomaterial-based drug delivery platform designed to improve the delivery of RNA therapeutics and other therapeutic molecules. The company offers a bioabsorbable silicon matrix combined with lipids and amino acids to enhance stability, solubility, targeting, transfection efficiency, and controlled release, enabling biotechnology and pharmaceutical companies to develop therapies across diverse disease indications.

Total raised£43M

Quality score66.7

Founded2006

HQ cityGuildford

Registered trials—

Employees18

Last financingLater Stage VC

# investors11

Investors: Clarendon Fund Managers, Croda International, Duncreggan Student Village, European Regional Development Fund (Brandenburg), Future Fund (UK), Innovate UK, Innovation Ulster, Invest Northern Ireland, Irish Technology Capital, Thrive AgriFood, Vickers Venture Partners

✎ Outreach notes

25 Vivan Therapeutics Therapeutic developerLondon 66.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of personalized therapeutics designed to transform cancer care. The company's technology follows the personal discovery process (PDP), a massive clinical trial for a single patient, where the genetic complexity of each patient's tumor network is engineered into a group of fruit flies and robotics are used to evaluate FDA-approved drugs including non-cancer drugs, enabling cancer patients with better treatment recommendations and developing new diagnostics and decision support tools to make cancer treatment more effective.

Total raised£6M

Quality score66.1

Founded2018

HQ cityLondon

Registered trials—

Employees23

Last financingAccelerator/Incubator

# investors17

Investors: Arben Ventures, BioIndustry Association, European Innovation Council, Freya Ventures, Granatus Ventures, Grow London, Harbr (Birmingham), Hub71, Innovate UK, National Institutes of Health, Nevcap, P4 Precision, Reflect Ventures, SFC Capital, The Francis Crick Institute, Voyagers.io, West Midlands Health Tech Innovation Accelerator

✎ Outreach notes

26 Wobble Genomics Review (unclear)Midlothian 65.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology firm intended to discover novel nucleic acid biomarkers with unprecedented sensitivity and accuracy. The company specializes in maximizing ribonucleic acid and deoxyribonucleic acid sequencing efficiency for the discovery and detection of nucleic acid biomarkers by combining biochemistry with bioinformatics, enabling medical researchers to maximize sampling efficiency during sequencing at lower costs.

Total raised£13M

Quality score65.6

Founded2020

HQ cityMidlothian

Registered trials—

Employees21

Last financingEarly Stage VC

# investors9

Investors: BGF (Financial Services), Eos Advisory, Innovate UK, IQ Capital Partners, Mercia Asset Management, Mercia Ventures, Old College Capital, Scottish Enterprise, The University of Edinburgh

✎ Outreach notes

27 T-Cypher Bio Therapeutic developerOxford 63.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of T-cell receptor-based therapeutics designed to offer a novel approach to cancer treatment. The company's therapies utilize state-of-the-art techniques to identify a broad range of potential targets by generating target screening libraries that directly identify functionally defined T-cell clones from disease tissues, for both solid tumors and other indications, enabling healthcare providers to adopt an end-to-end approach to cell therapy development and patient treatment.

Total raised£24M

Quality score63.7

Founded2015

HQ cityOxford

Registered trials—

Employees42

Last financingEarly Stage VC

# investors8

Investors: Borealis Ventures, Future Planet Capital, LifeArc Ventures, Medicxi, Oxford Investment Consultants, Oxford Science Enterprises, Perivoli Innovations, University of Oxford

✎ Outreach notes

28 BIOS Health Review (unclear)Cambridge 63.0

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of prosthetic connectors designed to standardize the connection between bionic devices and neural and soft-tissue systems within the body. The company's connectors are implanted medical devices that can be inserted into the end of an amputated limb, and they can precisely link nerve activity to specific conditions through the discovery of their neural biomarkers, enabling healthcare professionals to have neural control and feedback from prosthetic connectors easily.

Total raised£25M

Quality score63.0

Founded2015

HQ cityCambridge

Registered trials—

Employees25

Last financingAccelerator/Incubator

# investors34

Investors: Accelerate Cambridge, Allia Future Business Centre, AME Cloud Ventures, Ariel Poler, Cambridge Enterprise Ventures, Charles Songhurst, Cisco Systems, DigitalHealth.London Accelerator, Endure Capital, Fifty Years, Heuristic Capital Partners, Innovate UK, Investo (San Francisco), K5 Ventures, Kern Venture Group, MassChallenge, McGill Dobson Centre for Entrepreneurship, McGill University, MEDTEQ Invest, MicroVentures, Mitacs, National Institutes of Health, Neuromod Prize, OneStart, Philipp Moehring, Real Ventures, Selvedge Venture, Tech Nation Group, The Venture Collective, The Yope Foundation, Tiny Supercomputer Investment Company, Unreasonable Group, XTX Ventures, Y Combinator

✎ Outreach notes

29 Argonaute RNA Therapeutic developerCardiff 62.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of therapeutic medicines designed to harness the body's natural cell mechanisms to combat illness. The company's platform uses a novel method of stabilizing the small interfering ribonucleic acid, thereby avoiding a range of issues that create obstacles, enabling medical practitioners to get effective therapeutics to inhibit the production of specific proteins and treat life-threatening diseases.

Total raised£7M

Quality score62.4

Founded2015

HQ cityCardiff

Registered trials—

Employees8

Last financingLater Stage VC

# investors9

Investors: Bristol Private Equity Club, CatSci, Development Bank of Wales, Empirical Ventures, Fink Family Office, Johnathan Matlock, Science Angel Syndicate, Science Creates, Tiny Supercomputer Investment Company

✎ Outreach notes

30 Metrion Biosciences Review (unclear)Cambridge 60.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a contract research organization intended to focus on delivering a range of preclinical drug discovery screening services. The company's platform provides highly skilled electrophysiology screening services in multiple formats for medicinal chemistry support, and also offers flexible business models according to the scope of each program, with both fee-for-service and collaborative options and options to access integrated drug discovery services, enabling clients with the support of medicinal chemistry optimization programs, compliant cardiac safety profiling assays, neuroscience assays, and translational assays.

Total raised£10M

Quality score60.7

Founded2015

HQ cityCambridge

Registered trials—

Employees40

Last financingLater Stage VC

# investors7

Investors: Biomedical Catalyst, Eurostars, Gresham House Ventures, Innovate UK, Maven Capital Partners UK, O2h Ventures, SyndicateRoom

✎ Outreach notes

31 eXmoor Pharma Therapeutic developerBristol 58.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a contract development and manufacturing business intended for cell and gene therapy products. The company offers a range of services, including manufacturing strategy, process development consultancy, and bioprocess engineering, helping clients to design projects based on their needs and commercial objectives.

Total raised£52M

Quality score58.9

Founded2004

HQ cityBristol

Registered trials—

Employees71

Last financingPE Growth/Expansion

# investors3

Investors: Innovate UK, Kineticos Life Sciences Management, MVM Partners

✎ Outreach notes

32 Domainex Review (unclear)Saffron Walden 58.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Provider of drug discovery services intended to offer research facilities for developing advanced medicines. The company's services use biochemical binding technology to develop oncology drugs, including inhibitors of the kinases and epigenetics-related lysine methyltransferases, enabling healthcare professionals to tackle drug discovery problems against a wide range of drug targets.

Total raised£9M

Quality score58.3

Founded2001

HQ citySaffron Walden

Registered trials—

Employees95

Last financingSecondary Transaction - Private

# investors8

Investors: Innovate UK, Juno Capital, Longbow Capital, National Health and Medical Research Council, Takeda Ventures, The Institute of Cancer Research, UCL Ventures, University College London

✎ Outreach notes

33 Pencil Biosciences Review (unclear)Macclesfield 55.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of gene-editing technology designed to create a range of applications, like new therapeutic options for patients with rare diseases. The company's technology develops a novel genome modulation platform that helps to anticipate a wide impact across a range of applications, enabling medical professionals to overcome the challenges of gene editing associated with various technologies.

Total raised£10M

Quality score55.9

Founded2018

HQ cityMacclesfield

Registered trials—

Employees14

Last financingSeed Round

# investors12

Investors: Catapult Ventures, EMV Capital, Future Planet Capital, Innovate UK, Jonathan Milner, Martlet Capital, Meltwind Advisory, Northern Gritstone, O2h Ventures, Octopus Ventures, SyndicateRoom, UK Innovation & Science Seed Fund

✎ Outreach notes

34 PharmEnable Therapeutics Therapeutic developerCambridge 55.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a molecule drug designed to replicate the specificity of biologics in the form of small molecules. The company uses a unique and diverse virtual compound library in conjunction with computational screening programs to identify novel active chemical starting points against the most challenging biological targets, enabling the medical community to develop medicines such as a novel antibacterial agent or cancer treatment.

Total raised£10M

Quality score55.9

Founded2016

HQ cityCambridge

Registered trials—

Employees13

Last financingLater Stage VC

# investors23

Investors: Accelerate Cambridge, Andy Richards, Arrowfield Capital, BioIndustry Association, Cambridge Angels, Cambridge Enterprise Ventures, David Ford, EMV Capital, Heyford Trust, Ian Tomlinson, Jonathan Milner, Martlet Capital, Meltwind Advisory, MP Healthcare Venture Management, O2h Ventures, Parkwalk Advisors, Paul Forster, Pitch@Palace, R42 Group, SyndicateRoom, The Francis Crick Institute, University of Cambridge, Wren Capital

✎ Outreach notes

35 Quotient Therapeutics Review (unclear)London 55.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a platform intended to create transformative therapeutics with naturally selected targets. The company uses four key steps to study human natural target selection phenotyping, isolation, genotyping, and computation, enabling clients to direct us towards the best path for drug development.

Total raised£50M

Quality score55.8

Founded2022

HQ cityLondon

Registered trials—

Employees72

Last financingEarly Stage VC

# investors1

Investors: Flagship Pioneering

✎ Outreach notes

36 Fios Genomics Review (unclear)Edinburgh 55.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a drug discovery and development platform intended to provide an extensive range of bioinformatics data analysis services. The company's platform specializes in the analysis of datasets and recognizing patterns and trends associated with a trait, disease, or drug response, enabling clients to avail genomic, transcriptomic, metabolomic, and proteomics data analysis using bespoke and high-throughput workflows.

Total raised£4M

Quality score55.5

Founded2008

HQ cityEdinburgh

Registered trials—

Employees45

Last financingLater Stage VC

# investors5

Investors: Archangel Investors, Charles River Laboratories International, Scottish Enterprise, The University of Edinburgh, TRICAPITAL Angel Investors

✎ Outreach notes

37 Kinomica Review (unclear)Macclesfield 55.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a phosphoproteomic diagnostic platform designed to enhance tailored treatment decisions involving anticancer drug therapies. The company's platform provides a suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can access direct activity measurements of multiple endogenous kinases and comprehensive cell signal network coverage, enabling patients to determine disease mechanisms, while upscaling drug targeting and biomarker identification.

Total raised£13M

Quality score55.3

Founded2016

HQ cityMacclesfield

Registered trials—

Employees30

Last financingLater Stage VC

# investors11

Investors: Alderley Park, BGF (Financial Services), Claire Brown, Innovate UK, Longwall Ventures, Mercia Ventures, Michele Perkins, Pioneer Group, Puffin Point, Queen Mary University of London, Will Chawner

✎ Outreach notes

38 Rathlin Therapeutics Therapeutic developerLondon 55.0

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of brain-localized receptor antagonists designed for the treatment of diseases. The company offers specific receptors that modulate the main mechanism of action of such diseases, helping patients with unmet medical needs.

Total raised£27M

Quality score55.0

Founded2022

HQ cityLondon

Registered trials—

Employees4

Last financingEarly Stage VC

# investors3

Investors: Columbus Venture Partners, Forbion, OrbiMed

✎ Outreach notes

39 Pharmanovia Therapeutic developerBasildon 54.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a specialty pharmaceutical business focused on delivering quality branded prescription medicines to patients, prescribers and healthcare providers. The company specializes in acquiring, developing and marketing mature branded medicines globally and buys prescription-based medicines whose patents have expired and still have stable demand from patients in the fields of cardiovascular, women's health and endocrinology, neurology and gastroenterology, enabling clients to get their required medicines at an affordable rate.

Total raised£2,264M

Quality score54.5

Founded2013

HQ cityBasildon

Registered trials—

Employees338

Last financingDebt - General

# investors1

Investors: Triton Partners

✎ Outreach notes

40 Sentinel Oncology Therapeutic developerCambridge 54.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of oncology candidate drugs designed to treat primary brain tumours or systemic tumours. The company develops and commercialises therapeutics to treat cancer patients for unmet medical needs, enabling patients to get cures for cancer and other crucial diseases.

Total raised£3M

Quality score54.5

Founded2005

HQ cityCambridge

Registered trials—

Employees9

Last financingGrant

# investors6

Investors: Biomedical Catalyst, Cambridge Enterprise Ventures, East of England Development Agency, Innovate UK, Medeor Pharma, O2h Ventures

✎ Outreach notes

41 DIOSynVax Therapeutic developerHertford 53.2

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a vaccine antigen design company intended to accelerate vaccine development to maximize the protection against existing and future viruses. The company offers services that leverage technology to digitally design, immune-optimized selected and synthesized vaccines to achieve dramatic improvements in protection against emerging and re-emerging pathogens such as influenza, COVID-19, and viral hemorrhagic fevers, enabling doctors to treat and help patients recover quickly from diseases.

Total raised£10M

Quality score53.2

Founded2017

HQ cityHertford

Registered trials—

Employees17

Last financingLater Stage VC

# investors7

Investors: Coalition for Epidemic Preparedness Innovations, Flu lab, Gates Foundation, Innovate UK, Parkwalk Advisors, UK Department of Health, University of Cambridge

✎ Outreach notes

42 BioSure Therapeutic developerWaltham Abbey 53.2

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of pharmaceutical products designed to support the treatment of medical conditions. The company offers formulated medications with verified composition and stable performance, enabling healthcare providers to manage patient care across hospitals, clinics, and pharmacies.

Total raised£3M

Quality score53.2

Founded2011

HQ cityWaltham Abbey

Registered trials—

Employees12

Last financingBankruptcy: Liquidation

# investors3

Investors: Energy Laboratory, Perscitus, VentureFounders

✎ Outreach notes

43 Klona Biotech Therapeutic developerOxford 52.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a biotechnology company designed to revolutionize bioprinting with structural bio-integrated textiles for regenerative medicine and tissue engineering. The company offers new methods for rapid and scalable production of biological structures to fabricate structurally sound, patient-specific biological implants and accelerate pre-clinical testing and regulatory validation, enabling hospitals to have safe and reliable patient-specific organs that can be printed on demand.

Total raised£2M

Quality score52.7

Founded2025

HQ cityOxford

Registered trials—

Employees5

Last financingSeed Round

# investors6

Investors: Arben Ventures, Draper Associates, IndieBio, Outset Ventures, SOSV, Zee Prime Capital

✎ Outreach notes

44 Zentraxa Review (unclear)Bristol 52.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of biopolymers designed to assist various medical processes and functions. The company's biopolymers can circumvent previously existing bio-design limits imposed by conventional peptide synthesis, with one universal process and use a unique manufacturing process to produce biological adhesives, enabling clients to get assistance in various research and development processes.

Total raised£3M

Quality score52.6

Founded2017

HQ cityBristol

Registered trials—

Employees17

Last financingSeed Round

# investors16

Investors: Bristol Private Equity Club, Elbow Beach Capital, Empirical Ventures, Future Planet Capital, Future Planet Capital Regional, Innovate UK, KCP Nominees, Maven Cognition, Oliver Sexton, Parkwalk Advisors, Science Angel Syndicate, Science Creates, Setsquared Bristol, SyndicateRoom, UK Innovation & Science Seed Fund, University of Bristol

✎ Outreach notes

45 Rosemont Pharmaceuticals Review (unclear)Leeds 52.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Manufacturer of oral liquid formulations of off-patent and solid-dose pharmaceutical products intended for patients with swallowing difficulties. The company offers liquid and solid medications and also provides medicines for anesthesia, the cardiovascular system, the central nervous system, the endocrine system, the gastrointestinal system, infections, malignant disease and immunosuppression, and other diseases, thereby enabling patients to improve their health.

Total raised£10M

Quality score52.3

Founded1967

HQ cityLeeds

Registered trials—

Employees283

Last financingContinuation Fund Transaction

# investors—

Investors: —

✎ Outreach notes

46 Alethiomics Therapeutic developerOxford 52.0

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a pre-clinical biotech company intended to develop targeted therapies to treat a family of blood cancers. The company uses single-cell multi-omic technology to discover curative therapies and treatments, enabling medical professionals to provide treatments for myeloproliferative neoplasms that begin with mutations occurring in cancer stem cells in the bone marrow.

Total raised£8M

Quality score52.0

Founded2021

HQ cityOxford

Registered trials—

Employees11

Last financingSeed Round

# investors3

Investors: Cancer Research Horizons, Oxford Science Enterprises, University of Oxford

✎ Outreach notes

47 ScreenIn3D Review (unclear)Glasgow 51.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of advanced drug screening technologies and software designed to de-risk drug discovery. The company leverages microfluidic technology to generate physiologically relevant three-dimensional models of human disease, enabling pharmaceutical and biotechnology professionals to conduct throughput drug screening, reduce costs, and accelerate the drug discovery process using predictive, animal-free disease models.

Total raised£1M

Quality score51.9

Founded2018

HQ cityGlasgow

Registered trials—

Employees7

Last financingSeed Round

# investors10

Investors: Gabriel Investment Syndicate, Gabriel Investments, Innovate UK, Nidobirds Ventures, Scottish EDGE, Scottish Enterprise, Shancastle Investments, The University of Strathclyde, TRICAPITAL Angel Investors, University of Strathclyde Endowment

✎ Outreach notes

48 CNX Therapeutics Review (unclear)London 51.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Manufacturer of specialty pharmaceutical products intended to improve the lives of patients with neurological, psychiatric, and critical care conditions. The company licenses, commercializes, and distributes prescription medicines for central nervous system disorders, critical care, oncology, and hospital settings through strategic partnerships and pan-European distribution networks, enabling healthcare providers, hospitals, and pharmaceutical partners to improve patient access to essential medicines across global markets.

Total raised£4M

Quality score51.9

Founded1997

HQ cityLondon

Registered trials—

Employees66

Last financingContinuation Fund Transaction

# investors—

Investors: —

✎ Outreach notes

49 Isogenica Therapeutic developerEssex 51.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of versatile small-format antibodies designed to construct biotherapeutics for the treatment of cancer, inflammation, and other serious diseases. The company's antibodies can be assembled to create bispecific and multi-specific biotherapeutics or used to achieve targeted drug delivery as components of ADCs, cell and gene therapies, enabling medical research centers to provide a powerful discovery engine for single-domain biotherapeutics.

Total raised£6M

Quality score51.9

Founded1998

HQ cityEssex

Registered trials—

Employees23

Last financingGrant

# investors3

Investors: Horizon 2020, Innovate UK, KC Holding

✎ Outreach notes

50 Ubiquigent Therapeutic developerDundee 51.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Provider of drug discovery services intended to help clients drive the discovery and development of novel deubiquitylase modulators as powerful new therapeutics for areas of high unmet need. The company's IP-generating life sciences hybrid business is established for the development of novel deubiquitylase (DUB) enzyme inhibitors and offers DUB-focused drug discovery services that focus on the development and optimization of drug candidate compounds that target the system addressing a number of critical therapeutic areas, and an internal pipeline of drug discovery programs and are developing a strong IP portfolio encompassing inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and Deubiquitinase-Targeting Chimeras (DUBTACs), providing potential new starting points for client discovery programs through partnerships and out-licensing agreements, thereby initiating a range of drug discovery programs for the academic and pharmaceutical researchers to understand the role of the protein ubiquitin systems in regulating many aspects of cellular function.

Total raised£2M

Quality score51.7

Founded2009

HQ cityDundee

Registered trials—

Employees6

Last financingLater Stage VC

# investors7

Investors: Asterand Biosciences, Innovate UK, IP Group, Scottish Enterprise, UK Research and Innovation, University of Dundee, University of Dundee Endowment

✎ Outreach notes

51 Sistemic Review (unclear)Glasgow 50.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of microRNA analysis technology intended to offer products for the bioprocessing, cell therapy and drug discovery and development markets. The company focuses on the analysis of the information content of microRNA and other non-coding RNAs for applications in the development of cell therapies and drug repositioning, enabling healthcare professionals to easily develop cell therapies and drug repositioning without any hassle.

Total raised£4M

Quality score50.7

Founded2007

HQ cityGlasgow

Registered trials—

Employees7

Last financingLater Stage VC

# investors6

Investors: ChimaeraBio, Highland Venture Capital, Innovate UK, London & Scottish Investment Partners, Scottish Enterprise, TRICAPITAL Angel Investors

✎ Outreach notes

52 Morvus Therapeutic developerBrecon 50.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of novel drugs and diagnostics designed for the oncology sector. The company specializes in drug discovery and creates therapeutic drugs and diagnostics for lung cancer, tumors, and other oncological diseases using an inhalation route to deliver the drug to tumour sites, enabling medical professionals to use the potential agent to treat some skin cancers.

Total raised£18M

Quality score50.4

Founded2004

HQ cityBrecon

Registered trials—

Employees5

Last financingLater Stage VC

# investors4

Investors: Cardiff University, FusionIP, IP Group, National Institute for Health and Care Research

✎ Outreach notes

53 Ingenza Review (unclear)Penicuik 49.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology company intended to generate innovative biobased systems for a diverse range of customer problems. The company's services provide efficient, scalable bioprocesses for the manufacture of chemicals, biologics, pharmaceuticals, and biofuels, from sustainable sources, and have assembled integrated teams of scientists bringing together expertise across synthetic chemistry, informatics, molecular genetics, biochemistry, and fermentation scale-up, enabling clients to shorten the bioengineering design and test cycle and successfully construct bioprocesses.

Total raised—

Quality score49.8

Founded2002

HQ cityPenicuik

Registered trials—

Employees48

Last financingLater Stage VC

# investors6

Investors: Horizon 2020, Innovate UK, NZIP Acceleration, Scottish Enterprise, The FSE Group, The University of Edinburgh

✎ Outreach notes

54 ILC Therapeutics Therapeutic developerGlasgow 49.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of novel peptide therapeutics intended to find a cure against COVID-19, ARDS, Oncology, Psoriasis and Atopic Dermatitis. The company builds interferon medicines called hybrid interferons that take features of natural interferon subtypes and combine them into one new hybrid interferon molecule that is designed to deliver enhanced efficacy and improved safety over a range of high-value therapeutic areas, enabling healthcare professionals to improve patient outcomes and find a cure against diseases.

Total raised£13M

Quality score49.3

Founded2012

HQ cityGlasgow

Registered trials—

Employees8

Last financingLater Stage VC

# investors6

Investors: Eos Advisory, ILCT management, Medical Incubator Japan, Pioneer Group, Robert Kopple, Scottish Enterprise

✎ Outreach notes

55 Medicines Management Solutions Review (unclear)Leicester 49.0

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of GP pharmacist services and medicines management solutions for primary care. The company offers medication reviews, care home support, and long and short-term GP pharmacist services. MMS is approved by various Primary Care Organizations across England and offers services that can be funded via ARRS or directly.

Total raised—

Quality score49.0

Founded2007

HQ cityLeicester

Registered trials—

Employees6

Last financingBuyout/LBO

# investors—

Investors: —

✎ Outreach notes

56 ConsoneAI Review (unclear)Wetherby 48.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a disruptive technology intended for targeting the decisions that are made in the drug development process. The company offers a tool that helps accelerate the process of drug development, reduces the cost and time taken to get the medicines to market, allows medicines to be tested using software, removes the need for unnecessary environmental impacts, enabling businesses to predict toxicological effects and the viability of new drugs.

Total raised£1M

Quality score48.9

Founded2020

HQ cityWetherby

Registered trials—

Employees4

Last financingAccelerator/Incubator

# investors6

Investors: BioIndustry Association, Change Makers, Forward Partners Group, SFC Capital, Sixth Wave Ventures, Stevenage Bioscience Catalyst

✎ Outreach notes

57 Ridge Pharma Review (unclear)Reading 48.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a pharmaceutical company based in Reading, United Kingdom. The company focuses on the in-licensing and marketing of prescription medicines, enabling clients to receive drugs as per their requirements.

Total raised£4M

Quality score48.6

Founded2017

HQ cityReading

Registered trials—

Employees19

Last financingPE Growth/Expansion

# investors2

Investors: Mercia Ventures, NVM Private Equity

✎ Outreach notes

58 Mevox Review (unclear)London 47.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a vaccine innovation technology designed to protect health globally. The company's technology specializes in translating molecular characterization, design, and engineering into conformationally precise and optimized protein antigens which include neutralizing antibody levels than existing vaccines, enabling doctors to bring established vaccines and address significant unmet needs.

Total raised£6M

Quality score47.7

Founded2019

HQ cityLondon

Registered trials—

Employees3

Last financingEarly Stage VC

# investors2

Investors: Kenneth Kelley, Morningside Group

✎ Outreach notes

59 MatchBio Therapeutic developerLondon 47.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of targeted therapies designed to target immune cells to transform immunotherapy. The company focuses on treatments designed to address specific biological pathways involved in diseases, offering a more precise approach to treatment than traditional medications by providing synthetic receptors that enhance the sensitivity of chimeric antigen receptor based therapies, enabling the healthcare industry and patients to improve treatment efficacy and reduce side effects and relapses.

Total raised—

Quality score47.6

Founded2023

HQ cityLondon

Registered trials—

Employees10

Last financingBuyout/LBO

# investors2

Investors: Oxford Science Enterprises, University of Oxford

✎ Outreach notes

60 Origin Peptides Review (unclear)Linlithgow 47.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of custom peptide products designed for research and pharmaceutical applications. The company utilizes a novel one-pot aqueous synthesis method, which eliminates the need for hazardous organic solvents and iterative process steps, thereby reducing reaction volumes, improving the product manufacturing Index, and cost-effective production of these biological molecules, enabling the biotechnology and pharmaceutical market to develop new therapies and applications with a reduced environmental footprint.

Total raised£0M

Quality score47.3

Founded2018

HQ cityLinlithgow

Registered trials—

Employees9

Last financingGrant

# investors4

Investors: General Inception, Pioneer Group, Scottish Enterprise, UK Research and Innovation

✎ Outreach notes

61 Biosynth Review (unclear)Berkshire 47.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of drugs intended to serve diagnostic and pharmaceutical companies. The company specializes in carbohydrates, nucleosides, enzyme substrates, natural products and biochemicals for life science research and offers monosaccharides, oligosaccharides, polysaccharides, enzyme substrates, detergents and other related products, thereby enabling clients to meet their diagnostic and pharmaceutical product needs.

Total raised£0M

Quality score47.3

Founded1966

HQ cityBerkshire

Registered trials—

Employees122

Last financingBuyout/LBO

# investors2

Investors: BroadOak Capital Partners, Kohlberg Kravis Roberts

✎ Outreach notes

62 Spliceor Review (unclear)Cambridge 46.2

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a gene-therapy platform designed to treat cancer. The company's platform facilitates a novel curative treatment for certain types of aggressive cancers that do not respond well to current treatment and involves a common mechanism for therapeutic development against liver cancer and pancreatic cancer, enabling healthcare providers to treat cancer patients and improve their lives.

Total raised£1M

Quality score46.2

Founded2020

HQ cityCambridge

Registered trials—

Employees6

Last financingSeed Round

# investors7

Investors: Accelerate Cambridge, Ajith Sukumaran, Amadeus Capital Partners, Cambridge Enterprise Ventures, Cancer Research Horizons, Start Codon, University of Cambridge

✎ Outreach notes

63 Iqur Therapeutic developerLondon 46.2

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a vaccine research and development and molecular diagnostics firm headquartered in London, England. The company uses its proprietary tandem core technology to develop vaccines for infectious diseases, including a universal influenza vaccine, vaccines for dengue fever, Burkholderia morbidity and a vaccine for hepatitis C virus and uses virus-like particles (VLP) to stimulate the immune system and inoculate against pathogens.

Total raised£4M

Quality score46.2

Founded2003

HQ cityLondon

Registered trials—

Employees14

Last financingLater Stage VC

# investors4

Investors: IP Group, IP Ventures, University of Leeds, University of Southampton

✎ Outreach notes

64 Aspire Pharma Review (unclear)Petersfield 46.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Manufacturer of generic and specialty pharmaceutical products intended to create value and provide sustainability to patients and healthcare professionals. The company specializes in the development, licensing, and marketing of both branded and generic medicines, offering products including medical devices, diagnostics, and over-the-counter products targeted for both primary and secondary care.

Total raised—

Quality score46.1

Founded2009

HQ cityPetersfield

Registered trials—

Employees183

Last financingBuyout/LBO

# investors2

Investors: H.I.G. Europe, PFR Ventures

✎ Outreach notes

65 MICA Biosystems Review (unclear)Birmingham 46.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a cell stimulation platform designed to support new approaches to tissue engineering, biotechnology, and regenerative medicine via novel magnetic mechanostimulation. The company's platform applies static magnetic forces to biological material labeled or associated with magnetic material, enabling controlled cell differentiation and mechanical stimulation, thereby enabling researchers to develop novel technologies and innovative cell-based therapies for clinical use.

Total raised£2M

Quality score46.1

Founded2010

HQ cityBirmingham

Registered trials—

Employees8

Last financingAccelerator/Incubator

# investors4

Investors: European Commission, Innovate UK, Keele University, West Midlands Health Tech Innovation Accelerator

✎ Outreach notes

66 Zoi Environmental Technologies Review (unclear)London 45.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Manufacturer of biotechnology products intended for wastewater management in urban infrastructure. The company offers cost-efficient and regulation-compliant treatment systems, enabling industrial facilities, commercial centers, and utilities to reduce operational and maintenance expenses while meeting environmental standards.

Total raised—

Quality score45.9

Founded2012

HQ cityLondon

Registered trials—

Employees4

Last financingAccelerator/Incubator

# investors2

Investors: Pragma Capital Partners, Workup (Turkey)

✎ Outreach notes

67 Amprologix Therapeutic developerPlymouth 45.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of antimicrobial-resistant drugs designed to combat drug-resistant infections. The company utilizes cutting-edge machine learning algorithms to improve antibiotic properties, including nasal decolonization of methicillin-resistant Staphylococcus aureus, pneumonia, and surface skin infections, enabling clients to combat the growing problem of antibiotic resistance.

Total raised£1M

Quality score45.7

Founded2018

HQ cityPlymouth

Registered trials—

Employees5

Last financingLater Stage VC

# investors6

Investors: Ingenza, MassChallenge, Plutus Investment Group, Saudi Biotechnology Accelerator, UK Research and Innovation, University of Plymouth

✎ Outreach notes

68 Heart Biotech Review (unclear)Winchester 44.2

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of regenerative implants designed to restore natural tissue function in cardiovascular patients. The company specializes in bioengineered scaffolds featuring cell-free regenerative materials, dynamic tissue-shaping design, and full resorption capability, enabling pediatric and adult patients to regenerate living heart valves that grow, adapt, and eliminate the need for repeat surgeries.

Total raised£6M

Quality score44.2

Founded2014

HQ cityWinchester

Registered trials—

Employees5

Last financingLater Stage VC

# investors4

Investors: Innovate UK, MedTech Innovator, Norn Ventures, Sharjah Research Technology and Innovation Park

✎ Outreach notes

69 ABBio Therapeutic developerDundee 43.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of antibodies designed for the treatment of oncology and Alzheimer's diseases. The company's technology focuses on a specific range of tumor suppressor gene antibodies developed in research labs, enabling researchers and pharmaceutical companies to use the antibodies as drug targets to counter diseases.

Total raised—

Quality score43.8

Founded2020

HQ cityDundee

Registered trials—

Employees3

Last financingEarly Stage VC

# investors1

Investors: Innova Partnerships

✎ Outreach notes

70 Ryboquin Therapeutic developerGlasgow 43.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of gene therapy designed to treat cancer patients. The company's gene therapy uses nano-technology, commercializes human cancer medicines, and tumor apoptosis enhancer drugs to optimize chemotherapy, enabling patients to receive effective oncology therapies at an affordable cost.

Total raised£5M

Quality score43.6

Founded2013

HQ cityGlasgow

Registered trials—

Employees1

Last financingSecondary Transaction - Private

# investors1

Investors: Truetide

✎ Outreach notes

71 Perfect Balance Therapeutic developerTruro 43.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of novel therapeutics designed to rebalance the dysregulated immune system for inflammatory conditions. The company is currently operating in Stealth mode.

Total raised—

Quality score43.4

Founded2016

HQ cityTruro

Registered trials—

Employees2

Last financingLater Stage VC

# investors1

Investors: Medicxi

✎ Outreach notes

72 CS Pharmaceuticals Therapeutic developerLondon 42.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of ophthalmology and rare disease pharmaceuticals designed to address unmet medical needs in specialty therapeutic areas. The company focuses on discovering, in-licensing, and developing drug candidates that target the underlying pathophysiology of meibomian gland dysfunction and associated dry eye disease, with activities spanning molecule selection, preclinical evaluation, clinical trial design, and regulatory preparation, enabling ophthalmology specialists and healthcare providers to access new treatment options that address unmet clinical needs in ocular surface care.

Total raised£12M

Quality score42.8

Founded2020

HQ cityLondon

Registered trials—

Employees7

Last financingSecondary Transaction - Private

# investors—

Investors: —

✎ Outreach notes

73 Defenition Review (unclear)Harrogate 42.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of novel antibiotics designed to target bacterial flap endonuclease enzymes. The company's antibiotics aim at identifying and developing bacterial FEN inhibitors for use as antibiotic agents which are essential for DNA replications, enabling clinicians to repair and maintain genomic stability in pathogenic bacteria.

Total raised£1M

Quality score42.7

Founded2016

HQ cityHarrogate

Registered trials—

Employees—

Last financingGrant

# investors3

Investors: Innovate UK, IP Group, The University of Sheffield

✎ Outreach notes

74 Natantis Review (unclear)Edinburgh 42.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a cell-free deoxyribonucleic acid metagenomic workflow intended to identify sepsis-causing pathogens. The company's technology identifies viruses, bacteria, fungi, and various parasites at the species level, directly from a venous blood sample, providing clinicians with a sequencing assay and delivering a clinically actionable result in the form of a list of top pathogens.

Total raised£0M

Quality score42.3

Founded—

HQ cityEdinburgh

Registered trials—

Employees—

Last financingLater Stage VC

# investors5

Investors: Heriot-Watt University, Merck, SantanderX, Scottish Enterprise, UK Research and Innovation Medical Research Council

✎ Outreach notes

75 aTen Therapeutics Therapeutic developerEdinburgh 42.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of novel therapeutic antibodies designed to offer treatment for major diseases. The company's antibodies block cancer cell growth, invasion, and metastasis in a variety of tumor models with the help of anti-cancer agents for cancer cell proliferation, tumor invasion, and metastasis, enabling doctors to improve the lives of people with cancer and protect against developing metastases.

Total raised£2M

Quality score42.3

Founded2005

HQ cityEdinburgh

Registered trials—

Employees4

Last financingSecondary Transaction - Private

# investors1

Investors: Innovate UK

✎ Outreach notes

76 Bitrobius Genetics Review (unclear)Macclesfield 42.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a DNA transfer technology designed for gene and cancer therapy. The company engages in the development of synthetic gene transfer technology to solve the major problem with gene therapy, which is the inability to reach most of the cells in an affected organ or tissue, enabling doctors and researchers to study, develop, research, and manufacture new gene therapies and vaccines for the complete cure of a disease.

Total raised£2M

Quality score42.3

Founded2020

HQ cityMacclesfield

Registered trials—

Employees5

Last financingEarly Stage VC

# investors8

Investors: Catapult Ventures, Future Planet Capital, Innovate UK, KCP Nominees, Science Creates, SCVC, SynBioVen, UK Innovation & Science Seed Fund

✎ Outreach notes

77 AdoRx Therapeutics Therapeutic developerEdinburgh 42.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of novel drug therapeutics and a discovery company intended to identify new treatments for cancer. The company offers modulators targeting the adenosine pathway and addresses elevated adenosine levels in the tumor microenvironment, enabling healthcare providers to overcome immune suppression and deliver more effective therapies to patients.

Total raised£5M

Quality score42.3

Founded2017

HQ cityEdinburgh

Registered trials—

Employees3

Last financingEarly Stage VC

# investors2

Investors: Epidarex Capital, Sixth Element Capital

✎ Outreach notes

78 ReproGO Therapeutic developerBelfast 41.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a regenerative medicine company intended for stem cells and vascular biology-related drug development. The company aims to transform the treatment paradigm for patients grappling with severe and life-threatening conditions resulting from limited blood flow to tissues, enabling patients to undergo vascular therapies for reprogramming adult skin cells for use on CVD.

Total raised£0M

Quality score41.9

Founded2020

HQ cityBelfast

Registered trials—

Employees2

Last financingEarly Stage VC

# investors5

Investors: College Green Ventures, ICURe, Innovate UK Business Connect, QUBIS, Queen's University Belfast

✎ Outreach notes

79 Forcefield Therapeutics Therapeutic developerLondon 41.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Provider of therapeutics intended to treat heart disease. The company offers treatments to protect heart function by preventing the loss of cardiomyocytes following myocardial infarction, enabling doctors to preserve patients' heart muscle during heart attacks.

Total raised£8M

Quality score41.6

Founded2020

HQ cityLondon

Registered trials—

Employees8

Last financingEarly Stage VC

# investors2

Investors: Roche Venture Fund, Syncona

✎ Outreach notes

80 Myomaker Bio Therapeutic developerLondon 41.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of human muscle platforms designed for preclinical drug discovery, delivering data that boosts clinical trial success by replicating human muscle. The company's platform monitors muscle biology in health, exercise, disease injury and regeneration and can be applied across a range of preclinical muscle models, the models model muscle morphology and function and have been validated using pharmaceutical agents, enabling researchers to get preclinical muscle biology systems as per their requirement.

Total raised£0M

Quality score41.5

Founded2023

HQ cityLondon

Registered trials—

Employees8

Last financingEarly Stage VC

# investors3

Investors: ICURe, Loughborough University, SFC Capital

✎ Outreach notes

81 Talisman (Drug Discovery) Review (unclear)Cambridge 41.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a human neuroscience discovery platform designed to find disease-modifying therapeutics for Alzheimer's and other neurodegenerative diseases. The company offers an advanced iPSC platform, leveraging human stem cell-derived neural cell types and human genetics for rapid and relevant target identification and validation that accelerate drug discovery, enabling biotech firms, global pharma, and VCs to accelerate their preclinical neuroscience research with novel models of disease initiation and progression.

Total raised£0M

Quality score41.4

Founded2013

HQ cityCambridge

Registered trials—

Employees17

Last financingGrant

# investors4

Investors: Accelerate@Babraham, Innovate UK, O2h Ventures, University of Cambridge

✎ Outreach notes

82 ET-traps Therapeutic developerCambridge 41.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of novel therapies designed for sequestering pathologically elevated endothelin levels in the body. The company has developed an Fc-based fusion protein that has binding affinity in the picomolar range, enabling doctors to treat cardiovascular atherosclerosis, chronic kidney disease, pulmonary arterial hypertension, cancer, diabetes, and neurodegenerative disorders.

Total raised£1M

Quality score41.3

Founded2015

HQ cityCambridge

Registered trials—

Employees3

Last financingSeed Round

# investors2

Investors: Accelerate Cambridge, The Yope Foundation

✎ Outreach notes

83 Eleven Therapeutics Therapeutic developerCambridge 40.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of an extended durability mRNA therapeutics designed to transform ribonucleic acid drug development into a programmable processor. The company's pipeline is dedicated to tackling unmet medical needs in the realms of metabolic, endocrinologic, and infectious diseases by the utilization of proprietary high-throughput AI-enabled screening platforms, strategically employed to enhance the stability and facilitate their targeted and selective delivery, enabling scientists to have fully programmable ribonucleic acid molecules with superior durability and specificity.

Total raised£22M

Quality score40.9

Founded2020

HQ cityCambridge

Registered trials—

Employees31

Last financingAccelerator/Incubator

# investors7

Investors: Entrée Capital, Gates Foundation, GUTS, Innovate UK, Kindred Capital, NFX, Saras Capital (England)

✎ Outreach notes

84 Pronec Therapeutic developerMacclesfield 40.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of cancer therapies designed for anti-cancer drugs that operate through a novel mechanism. The company's therapy uses proprietary peptides and causes tumors to die with advanced medical innovations, enabling doctors to identify a lead candidate molecule that causes necrosis of a wide range of tumor cell lines in culture without affecting normal cell lines.

Total raised£0M

Quality score40.8

Founded2015

HQ cityMacclesfield

Registered trials—

Employees—

Last financingSecondary Transaction - Private

# investors2

Investors: Catapult Ventures, Pxn Ventures

✎ Outreach notes

85 FabricNano Review (unclear)London 39.8

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of enzyme-based biocatalyst technologies designed to enable a sustainable, cell-free alternative to traditional industrial and household chemistry. The company offers systems that pair enzymes with natural materials for applications such as soil CO2 sequestration and toxin capture in home laundry, enabling industrial customers and consumers to reduce environmental impact and adopt lower-carbon, safer chemical processes.

Total raised£25M

Quality score39.8

Founded2018

HQ cityLondon

Registered trials—

Employees8

Last financingEarly Stage VC

# investors20

Investors: Alexander Moscho, Arvind Gupta, Atomico, Backed, Biz Stone, BoxOne Ventures, Emma Watson, Entrepreneurs First, European Investment Fund, Gloria Baeuerlein, Hoxton Ventures, Ian Hogarth, Innovate UK, Michael Stoppelman, Milad Alucozai, Olima Ventures, Pace Ventures, Tania Boler, Transition Ventures, Vijay Pandurangan

✎ Outreach notes

86 Five Alarm Bio Therapeutic developerCambridge 38.9

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of anti-aging therapeutics designed to reduce the effects of aging on the human body. The company offers small-molecule-based drug development programs that strengthen cellular defense mechanisms against accumulated damage, enabling patients affected by age-related conditions to preserve healthy cell function and slow the progression of diseases associated with aging.

Total raised£1M

Quality score38.9

Founded2016

HQ cityCambridge

Registered trials—

Employees3

Last financingSeed Round

# investors6

Investors: Cambridge Angels, Innovate UK, InnovateUK, Meltwind Advisory, O2h Ventures, SyndicateRoom

✎ Outreach notes

87 Anastasis Biotec Therapeutic developerLondon 38.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of cancer therapeutics designed to serve as a novel, effective, and proprietary treatment method for various types of cancer. The company's therapeutics act as cancer pathway inhibitors that prevent rogue cancer cells of tumors having critical mutations from multiplying uncontrollably, caused by DNA abnormalities in important pathways involved in the generation of cancer and cancer stem cells, enabling oncologists to deliver tailor-made therapeutics to patients with cancers that express specific cancer-driving mutations.

Total raised£0M

Quality score38.7

Founded2016

HQ cityLondon

Registered trials—

Employees4

Last financingEquity Crowdfunding

# investors2

Investors: Innovate UK, Patha Capital

✎ Outreach notes

88 Pebble Review (unclear)Wilmslow 38.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology company intended to provide an alternative to large animal experimentation via ex vivo organ and tissue perfusion. The company offers living organ systems models and evaluates novel therapies, biomedical materials, and medical devices in physiological environments where tissue function and metabolism are restored, enabling medical technology and pharma businesses to track the disease and cure.

Total raised£0M

Quality score38.1

Founded2018

HQ cityWilmslow

Registered trials—

Employees14

Last financingEarly Stage VC

# investors1

Investors: Catapult Ventures

✎ Outreach notes

89 Evariste Therapeutic developerLondon 37.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of an artificial intelligence-enabled platform designed to advance synthetic lethal oncology. The company's platform identifies novel synthetic lethal targets and biomarkers and develops small-molecule therapeutic drug candidates, enabling clients to discover and develop cancer treatments.

Total raised£8M

Quality score37.7

Founded2017

HQ cityLondon

Registered trials—

Employees9

Last financingAccelerator/Incubator

# investors2

Investors: BioIndustry Association, Change Makers

✎ Outreach notes

90 BioAscent Review (unclear)Motherwell 36.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Provider of integrated drug discovery services intended to reach key stages of the drug discovery process. The company offers a range of services, including target analysis, bespoke screening strategies, compound screening, and data management, enabling pharmaceutical businesses to maximize their lead findings and increase the success rate of discovery projects at a lower cost.

Total raised£2M

Quality score36.4

Founded2013

HQ cityMotherwell

Registered trials—

Employees77

Last financingLater Stage VC

# investors2

Investors: Maven Capital Partners UK, Pioneer Group

✎ Outreach notes

91 Blossom (Pharmaceuticals and Biotechnology) Review (unclear)London 36.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Provider of a cannabis cultivation facility intended for the production and logistics of medical cannabis. The company engages in the cultivation and supply of a range of pharmaceutical-standard medical cannabis products directly from their farms that are used for treating several diseases and other medical purposes, enabling clients to access proprietary medicinal cannabis genetics and products.

Total raised£3M

Quality score36.3

Founded2019

HQ cityLondon

Registered trials—

Employees59

Last financingEarly Stage VC

# investors1

Investors: Deepbridge Capital

✎ Outreach notes

92 Connexin Therapeutics Review (unclear)York 35.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a medical platform intended to develop novel drugs to protect vision and prevent blindness. The company's offerings include discovering novel compounds that protect retinal neurons from threats posed by glaucoma, diabetic retinopathy, and ophthalmic conditions, enabling doctors to treat patients with progressive glaucoma and related conditions.

Total raised£0M

Quality score35.3

Founded2018

HQ cityYork

Registered trials—

Employees2

Last financingEarly Stage VC

# investors1

Investors: Oxford Technology Management

✎ Outreach notes

93 Everna Therapeutic developerLondon 35.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology company intended to develop drugs for age-related diseases. The company offers stem cell models that cause disease-modifying effects on several diseases of aging, enabling medical professionals to help patients to fight neurodegenerative, atherosclerosis, and other diseases.

Total raised—

Quality score35.1

Founded2016

HQ cityLondon

Registered trials—

Employees3

Last financingLater Stage VC

# investors9

Investors: Aera VC, Birgir Magnusson, Capitoria, Harry Briggs, Justin Mateen, Social Impact Capital, Soma Capital, The Venture Collective, Victor Orlovski

✎ Outreach notes

94 iEthico Review (unclear)Coventry 33.7

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a supply chain software designed to resolve drug supply and shortage issues by using big data and networks. The company have two products; MedSourcing Hub - regulated inverse marketplace for procuring medicines and MedSupply Intelligence - data solution combining disparate sources of public, private and proprietary data, enable to deliver intelligence about the real time medicine supply situation nationally and internationally, it optimize the use of medicines in the supply chain, reducing medicine shortages and waste medication.

Total raised£2M

Quality score33.7

Founded2020

HQ cityCoventry

Registered trials—

Employees8

Last financingAccelerator/Incubator

# investors7

Investors: Conduit Connect, Future Planet Capital, Future Planet Capital Regional, Grow Digital Health Midlands, Tiago Galvao, UK Innovation & Science Seed Fund, West Midlands Health Tech Innovation Accelerator

✎ Outreach notes

95 Spirea Review (unclear)Harrogate 31.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Develoepr of an antibody-drug conjugate intended for cancer treatment and improving the lives of patients. The company offers payload loading, broad payload compatibility, controlled pharmacokinetics, precise targeting, and flexible conjugation chemistry to be specifically directed to the tumor cell and that resulting in an increase in therapeutic effect whilst substantially reducing debilitating side effects, enabling biotech and pharmaceutical developers to build safer, more effective cancer therapies with reduced off-target effects.

Total raised£5M

Quality score31.6

Founded2015

HQ cityHarrogate

Registered trials—

Employees8

Last financingLater Stage VC

# investors14

Investors: Accelerate Cambridge, ACF Investors, Cambridge Angels, Cambridge Enterprise Ventures, Innovate UK, IP Group, Jonathan Milner, Meltwind Advisory, O2h Ventures, Parkwalk Advisors, R42 Group, Start Codon, SyndicateRoom, University of Cambridge

✎ Outreach notes

96 Pheno Therapeutics Therapeutic developerEdinburgh 30.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of remyelinating therapies designed to halt disability progression in demyelinating diseases such as acute optic neuritis and multiple sclerosis. The company discovers and develops small molecule therapeutics that promote remyelination by blocking a receptor called GPR17 which inhibits the brain's natural repair process, enabling medical professionals to enhance the repair of damaged myelin sheaths in their patients.

Total raised£6M

Quality score30.3

Founded2018

HQ cityEdinburgh

Registered trials—

Employees8

Last financingLater Stage VC

# investors4

Investors: Advent Life Sciences, LifeArc Ventures, Old College Capital, Scottish Enterprise

✎ Outreach notes

97 Aston Particle Technologies Review (unclear)Birmingham 29.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of particle engineering technology designed to process drugs without the use of solvents and heat. The company specializes in engineering microparticle surfaces by deposition of fine, cohesive secondary material, giving rise to tailored composite particles, providing businesses with cost-effective, environment-friendly, and reliable just-in-time manufacturing capabilities.

Total raised£2M

Quality score29.6

Founded2016

HQ cityBirmingham

Registered trials—

Employees9

Last financingAccelerator/Incubator

# investors7

Investors: Aston University, Aston University Endowment, DSW Ventures, ICURe, Innovate UK, Mercia Asset Management, West Midlands Health Tech Innovation Accelerator

✎ Outreach notes

98 AtoCap Review (unclear)London 26.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a microencapsulation technology designed to deliver generic antibiotics for urinary tract infection with chemotherapeutics into a multi-layered capsule. The company's technology utilizes advanced electrohydrodynamic production methods to create microbubbles and capsules, enabling healthcare providers to effectively administer medications while improving patient outcomes and reducing the recurrence rates of infections.

Total raised£2M

Quality score26.6

Founded2011

HQ cityLondon

Registered trials—

Employees4

Last financingLater Stage VC

# investors5

Investors: Impact Planet Ventures, Mustard Seed + Partners, Oxford Innovation Finance, UCL Ventures, University College London

✎ Outreach notes

99 CELEX Oncology Review (unclear)London 26.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology platform intended to support the development of targeted cancer therapies. The company offers research-driven therapeutics based on long-term studies and biological understanding, enabling patients with complex tumors access to focused treatment approaches.

Total raised£0M

Quality score26.3

Founded2016

HQ cityLondon

Registered trials—

Employees9

Last financingAccelerator/Incubator

# investors3

Investors: EIT Health, Grow London, Namier Capital Partners

✎ Outreach notes

100 Vaccicure Review (unclear)London 25.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biopharma company intended to develop fusion peptides for gastrointestinal cancers. The company's formulated peptides stimulate the immune system to produce endogenous polyclonal antibodies to gastrin without the risks and limitations associated with serum-derived polyclonal treatment or monoclonal antibody therapy, enabling doctors with a safer and potentially more adaptable treatment option.

Total raised£4M

Quality score25.6

Founded2014

HQ cityLondon

Registered trials—

Employees8

Last financingSecondary Transaction - Private

# investors—

Investors: —

✎ Outreach notes

101 Libero Pharma Review (unclear)Edinburgh 25.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a transdermal naltrexone patch designed to deliver naltrexone transdermally instead of a tablet or intramuscular injections. The company's transdermal patch mitigates the issue associated with existing formulations for use in the management of opiate addiction and alcohol use disorder and offers an alternative way of taking naltrexone, enabling doctors to treat patients with the disorder without any common naltrexone side effects.

Total raised£3M

Quality score25.5

Founded2018

HQ cityEdinburgh

Registered trials—

Employees5

Last financingEarly Stage VC

# investors2

Investors: Highland Venture Capital, TRICAPITAL Angel Investors

✎ Outreach notes

102 VascVersa Therapeutic developerBelfast 23.5

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of regenerative medicine designed to deliver new cell therapies that promote vascular regeneration and repair. The company's technology provides a unique cell therapy for blood vessel regeneration by stimulating new blood vessel formation, leading to an improved blood supply and long-term healing, enabling healthcare professionals to treat patients suffering from ischaemic diseases.

Total raised£1M

Quality score23.5

Founded2018

HQ cityBelfast

Registered trials—

Employees6

Last financingSeed Round

# investors9

Investors: Clarendon Fund Managers, College Green Ventures, Halo Business Angel Network, ICURe, Innovate UK, Innovation Investment Fund, Invest Northern Ireland, QUBIS, Queen's University Belfast

✎ Outreach notes

103 GlykoGen Therapeutic developerAberdeen 23.4

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of anti-glycan antibodies designed to produce fighting agents for cancer treatment and diagnostics. The company's engineered monoclonal antibodies are produced using their novel immunization process to target carbohydrates found on the surface of cancerous cells, enabling healthcare organizations and pharmaceutical companies to target hard-to-treat cancers, including pancreatic cancer.

Total raised£1M

Quality score23.4

Founded2016

HQ cityAberdeen

Registered trials—

Employees2

Last financingLater Stage VC

# investors4

Investors: David Mason, Equity Gap, Highland Venture Capital, Scottish Enterprise

✎ Outreach notes

104 Kairos Biotech Review (unclear)Denbighshire 23.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of small molecule-based immunotherapy and diagnostic technology designed to improve transplant outcomes. The company's platform enhances transplant options by utilizing small-molecule immunomodulators, non-invasive biomarker-based diagnostics, and tolerance induction strategies, enabling the health industries to access integrated therapeutic and diagnostic tools that promote transplantation tolerance and improve patient outcomes.

Total raised£2M

Quality score23.1

Founded2019

HQ cityDenbighshire

Registered trials—

Employees6

Last financingLater Stage VC

# investors2

Investors: EchiumBio Holding, Myosotis Investments

✎ Outreach notes

105 Singula Bio Therapeutic developerOxford 21.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a biotechnology firm specializing in the development of novel neoantigen-based cell therapies to treat cancer. The company focuses on advancing immunological, medical, surgical, and computational technologies to improve selective therapies for difficult-to-treat solid malignancies such as ovarian cancer, enabling healthcare professionals with individualized cell therapy options for cancer patients to prevent recurrence and prolong survival.

Total raised£3M

Quality score21.3

Founded2020

HQ cityOxford

Registered trials—

Employees8

Last financingEarly Stage VC

# investors3

Investors: Cancer Research Horizons, Oxford Science Enterprises, University of Oxford

✎ Outreach notes

106 Stratosvir Therapeutic developerIngatestone 21.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of immunotherapy intended to improve the clinical treatment of solid tumors and their metastases. The company engineers a cancer-killing virus to be used intravenously to deliver medicinal payloads within the tumor to stimulate and reprogram the immune system to attack and destroy cancer, enabling cancer patients to improve their immune system in their fight for effective, safe, non-toxic cancer treatments that increase the quality of life and survival.

Total raised£0M

Quality score21.1

Founded2020

HQ cityIngatestone

Registered trials—

Employees6

Last financingEarly Stage VC

# investors5

Investors: Cancer Research Horizons, Deep Science Ventures, O2h Ventures, Proven Connect, Stevenage Bioscience Catalyst

✎ Outreach notes

107 Bilitech Review (unclear)Hitchin 19.3

▸

Target	—
Modality	—
Design	—
Mechanism	—

Operator of a cellular therapy platform intended for regenerative medicine for biliary disorders. The company has advanced organoid-based cellular therapies to repair or replace damaged bile duct tissues, enabling patients to treat their disease.

Total raised£1M

Quality score19.3

Founded2017

HQ cityHitchin

Registered trials—

Employees2

Last financingEarly Stage VC

# investors2

Investors: Cambridge Enterprise Ventures, University of Cambridge

✎ Outreach notes

108 Genprice Review (unclear)Potters Bar 18.1

▸

Target	—
Modality	—
Design	—
Mechanism	—

Developer of a technology and service platform designed to formulate and manufacture pharmaceutical nanomedicines, including lipid nanoparticles, liposomes, and hybrid delivery systems. The company's platform offers advanced NanoSizer extrusion technologies, ProFECT nanoparticle formulations, and end-to-end cGMP manufacturing capabilities, enabling pharmaceutical and biotechnology companies, academic research labs, and clinical facilities to efficiently develop and produce therapeutics and vaccines with high precision and reproducibility.

Total raised£2M

Quality score18.1

Founded2015

HQ cityPotters Bar

Registered trials—

Employees2

Last financingLater Stage VC

# investors2

Investors: Boyd Venture Challenge, Innov865 Alliance

✎ Outreach notes

109 Parkure Review (unclear)Glasgow 7.6

▸

Target	—
Modality	—
Design	—
Mechanism	—

Provider of drug discovery services intended to find a cure for Parkinson's disease. The company's services include drug testing procedures by using fruit flies, thereby helping the medical industry to find a treatment that stops the nerve cell degeneration process.

Total raised£0M

Quality score7.6

Founded2014

HQ cityGlasgow

Registered trials—

Employees3

Last financingLater Stage VC

# investors3

Investors: LAUNCH.ed, The Scottish Government, The University of Edinburgh

✎ Outreach notes

★ Project Argonaut

Project Asclepius

Your file has downloaded

New project

Add a company

Delete this project?

Eliminate “Curve Therapeutics”?

Scoring weights

How the Score is calculated

Rate - Company

Edit — NeoPhore

Import from spreadsheet

Imported source